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ABSTRACT
During the 20th century, significant strides were made in curtailing the burden of
childhood diarrhea, including advances in vaccine research, the advent of antibiotics, improved
water and sanitation, and expanded access to health information across the globe. Despite this
progress, today diarrhea ranks second only to pneumonia as a leading cause of mortality in
children under five years, with a disproportionate burden of 90% of diarrheal deaths in South
Asia and Sub-Saharan Africa. Additionally, substantial morbidity due to diarrhea persists in
young children, with more than 45 million disability-adjusted life years (DALYs) lost due to
diarrhea in 2015. Long-term consequences of childhood diarrhea include undernutrition, impaired
gut function, altered gut microbiota, and compromised cognitive development.
The 21st century presents an opportunity to eliminate the health disparity affecting
millions of children suffering disproportionately from preventable diarrheal diseases. Recent
advances in molecular laboratory technology have enabled detailed assessment of diarrheal
burden and etiology, illuminating the highest burden pathogens for focused interventions. Among
the top diarrheal pathogens, rotavirus (RV) is the leading cause of diarrhea-attributable death in
the first year of life. While we have vaccines against RV, these vaccines consistently
underperform in low and middle-income countries (LMICs) with efficacy of 18% to 61%
compared to > 85% efficacy in high income countries. Reasons for rotavirus vaccine
underperformance remain unclear, and no vaccines are available for other high burden diarrheal
pathogens. This requires consideration of complementary and alternative interventions for
diarrhea prevention.
To assess factors related to rotavirus vaccine performance, we enrolled a 700-infant birth
cohort in an urban slum of Dhaka, Bangladesh, in the Performance of Rotavirus and Oral Polio
Vaccines in Developing Countries (PROVIDE) study: a randomized controlled trial of a 2-dose
monovalent oral rotavirus vaccine (RV1). With a primary outcome of any rotavirus diarrhea
(RVD) post-vaccination to one year, we conducted biweekly home-based diarrhea surveillance
with rotavirus antigen detection in diarrheal stools by ELISA. We found RV1 efficacy of 51%
(95% CI 33.8–63.7) in per protocol analysis. Importantly, among 12 explanatory variables tested
for association with RVD, serum zinc concentration (SZC) in infants at week 18 associated with
risk of RVD up to one year (OR 0.77, 95% CI 0.66–0.91), independent of vaccination status. This
finding led to broader investigation of the relationship between zinc status and diarrhea in the
PROVIDE cohort.
Among 577 PROVIDE infants, 16.5% were zinc deficient at week 18 (SZC < 65μg/dL).
By logistic regression, zinc deficient infants had increased odds of diarrhea in the first year of life
compared to zinc replete infants (OR 2.76, 95% CI 1.08–7.04), and they were nearly 4 times
more likely to have diarrhea of viral etiology (OR 3.94, 95% CI 1.55–10.03). Furthermore, in
Kaplan Meier analysis we found a strong correlation between zinc deficiency and time to first
episode of viral diarrhea (median survival 27 vs 33 weeks in zinc deficient vs non-deficient
infants, p <0.0001), with zinc deficient infants at 55% greater risk of viral diarrhea (HR 1.55,
95% CI 1.21 – 1.99).
Our results indicate further consideration of zinc as a critical and modifiable co-factor
in ameliorating the burden of childhood viral diarrhea. Carefully designed trials of zinc
supplementation interventions could determine whether zinc may fill the gap in protection against
childhood viral diarrhea, and inquiries into the zinc-diarrhea molecular pathway could elucidate
mechanisms for focused development of future interventions.
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CHAPTER 1: REVIEW OF THE EPIDEMIOLOGY, ETIOLOGY AND
POTENTIAL PREVENTIVE INTERVENTIONS FOR CHILDHOOD DIARRHEA
IN LOW AND MIDDLE INCOME COUNTRIES

1.1. Introduction
During the 20th century, significant strides were made in curtailing the burden of
childhood diarrhea, including advances in vaccine research, the advent of antibiotics,
improved water and sanitation, and expanded access to health information across the
globe. Despite this progress, today over half a million children die from diarrheaassociated complications before their fifth birthday [1]; almost all of them in South Asia
and Sub-Saharan Africa. The 21st century presents an opportunity to incorporate past
successes with cutting-edge basic science and excellent clinical research to drive our
understanding and elimination of the persistent public health challenge of childhood
diarrhea.

To that end, the objective of this review is to identify optimal preventive interventions to
address the health disparity affecting millions of children suffering disproportionately
from preventable diarrheal diseases. This work constitutes a fully translational inquiry
beginning with a review of the global epidemiology of childhood diarrheal morbidity and
mortality, including our recently expanded understanding of diarrheal burden and
etiology. This brings into sharp relief questions about effective prevention strategies
against lead diarrheal pathogens. Review of currently available diarrhea interventions
follows, with particular emphasis on zinc for diarrhea prevention based on results from
1

original research in Bangladesh on rotavirus vaccine efficacy (Chapter 2), which led to
observations correlating zinc deficiency with increased risk of viral diarrhea (Chapter 3).
Review of the zinc literature culminates with hypotheses on the molecular mechanisms
involved in the zinc-diarrhea pathway and evaluation of evidence on the effectiveness of
zinc supplementation for diarrhea prevention. The review ends with discussion of
unanswered questions and future directions.

1.2. Epidemiology of childhood diarrhea
In 2000, the global community set ambitious priorities for ameliorating poverty and
public health disparities in the 21st century with the declaration of the United Nations’
(UN) Millennium Development Goals. One of the eight targets agreed by UN member
states was a two-thirds reduction in child mortality by 2015. This goal brought into focus
the leading causes of mortality in children under 5 years, among which diarrhea ranks
second only to pneumonia in the post-neonatal period [2]. Diarrhea-attributable mortality
can result from either acute or chronic diarrhea, with dehydration and malnutrition as the
immediate cause of death from each condition, respectively.

Despite significant progress, the target reduction in child mortality is yet to be met, with
overall deaths declining one third from 9.9 million in 2000 to 6.3 million in 2013.
Diarrhea-attributable mortality has decreased at an annual rate of reduction of 6.5% since
2000; however diarrhea still accounts for over half a million child deaths annually, with a
disproportionate burden of 90% of diarrheal mortality in South Asia and Sub-Saharan
Africa [1-3], as shown in Figure 1.1..
2

Figure 1.1. Disproportionate burden of diarrheal mortality in South Asia and Sub-Saharan Africa,
2015 (From: Global Burden of Diseases Diarrhoeal Diseases Collaborators [3])

In addition to the challenge of reducing diarrhea-attributable mortality, substantial
morbidity due to diarrhea persists in young children. Recent analysis estimates more than
45 million disability-adjusted life years (DALYs) lost due to diarrhea and approximately
one billion episodes of diarrhea in children under 5 in 2015 [3]. Again, this burden falls
disproportionately on children in South Asia and Sub-Saharan Africa. Diarrheal
incidence decreased more slowly than mortality over the past few decades, with a
reduction from 3.4 to 2.9 episodes per child-year between 1990 and 2010 [4].

The long-term consequences of childhood diarrhea are just beginning to be understood
and include undernutrition (linear growth faltering and underweight), impaired gut
function, dysregulation of inflammatory and immune responses, altered microbiota, and
compromised cognitive development [5-8]. Collectively, these sequelae contribute to
decreased productivity and poor health outcomes into adulthood.

3

1.2.1. Epidemiology of viral diarrhea
Very little has been published on the epidemiology of viral diarrhea as a discrete
etiology. Diarrheas of viral etiology share a few key features. First, viral diarrhea knows
no boundaries. Rotavirus, the leading cause of childhood diarrhea globally (see below),
accounted for the highest burden of childhood diarrhea in the United States and other
high income countries (HICs) prior to vaccine introduction in the 2000’s [9]. Similarly,
other top viral pathogens are found to cause diarrhea across the globe, regardless of
national income or infrastructure. Diarrheal viruses tend to infect humans early in life,
with the highest rates of viral diarrhea due to rotavirus, adenovirus, norovirus, sapovirus
and astrovirus all occurring in children < 2 years [9]. Clinically, viral diarrheas are often
grouped together as relatively short duration and self-limiting; these clinical observations
from HICs may not be relevant in LMICs where children develop under different living
conditions and may be pre-disposed to longer duration, greater severity or increased risk
of viral diarrhea.

1.3. Etiology of diarrhea
In order to identify optimal interventions to address the continued burden of diarrheal
morbidity and mortality, scientists recognized the need to better understand the etiology
of childhood diarrhea, particularly in low and middle-income countries (LMICs). To this
end, two landmark, multi-site studies were conducted between 2007–2014, enrolling over
24,000 children across 12 countries in South Asia, Africa and South America: the Global
Enteric Multicenter Study (GEMS), and the Malnutrition and Enteric Disease Study
(MAL-ED). GEMS was a case-control study of moderate-to-severe diarrhea in children
4

age 1-59 months, while MAL-ED was a longitudinal birth cohort with community-based
diarrheal detection (i.e. milder cases) in which children were enrolled at birth and
followed for 2 years including collection of both diarrheal and asymptomatic stools.
Despite different study designs, the top pathogens contributing to attributable incidence
of diarrhea in GEMS and MAL-ED were similar, particularly in the first year of life.

Statistical methods for determining attributable incidence in GEMS and MAL-ED are
extensively detailed elsewhere [10, 11], and include first estimation of pathogen-specific
attributable fractions by Quantification Cycle (Cq) read-outs from quantitative
polymerase chain reaction (PCR) TaqMan Array Card (TAC) assay (detailed below).
Attributable fractions per pathogen were adjusted for prevalence of asymptomatic
carriage by odds of detection in cases vs controls, Cq value, quantity of co-pathogens,
study site, age and sex. Attributable incidence was then calculated from attributable
fraction estimates based on previous methods [12].

Rotavirus (RV) accounted for the highest attributable incidence of diarrhea during
infancy in all study sites where RV vaccines had not been introduced, and RV remained
the fifth leading cause of diarrhea in countries with RV vaccines [10, 11]. This aligns
with estimates from the World Health Organization’s (WHO) Global Rotavirus
Surveillance Network that approximately 40% of hospitalizations for acute diarrhea in
children under 5 in LMICs are due to rotavirus [13].

5

Although the GEMS and MAL-ED studies showed some geographic heterogeneity in
pathogen prevalence, other important diarrheal agents in the first year of life were
adenovirus 40/41, Shigella spp, Campylobacter spp, heat-stable enterotoxigenic E. coli
(ST-ETEC), and Cryptosporidium spp. In GEMS, 77.8% of attributable diarrhea was due
to RV and these five pathogens [10]. Notably, in MAL-ED, norovirus GII was the highest
burden diarrheal pathogen in countries with RV vaccine, a trend also seen in the United
States after introduction of RV vaccines in 2006 when norovirus GII replaced rotavirus as
the leading cause of acute gastroenteritis in children [1, 14].

1.3.1. Next generation diagnostic tools
The findings in both the GEMS and MAL-ED studies were facilitated by a next
generation molecular laboratory assay, the quantitative polymerase chain reaction (PCR)
TaqMan Array Card (TAC). TAC originated as a tool for gene expression studies and
was adapted for detection of respiratory and bioterror pathogens in 2010-2012. In 2012,
the assay was developed for stool-based enteropathogen detection at the University of
Virginia [15]. The TAC platform consists of a set of individual, microbe-specific, probebased assays assembled on a single card for simultaneous nucleic acid detection of
multiple pathogens per stool sample for up to 42 pathogen targets per card at present. The
assay read-out is a quantification cycle value (Cq) indicating the amplification cycle
number at which flouresced pathogen-specific nucleic acid is detectable above
background. Similar to CT values for other PCR-based platforms, the positive detection
range for TAC Cq has been established as 0 < Cq < 35 based on comparator studies with
conventional and other PCR methods [15, 16].
6

The TAC assay addresses some of the shortcomings of conventional lab methods for
pathogen detection (i.e. culture, microscopy, ELISA and PCR), including: time and cost
associated with multiple tests on individual stools, limited comparability across sites
using different detection methods for specific pathogens, risk of contamination of
specimens or assays when moving between platforms, and most importantly, poor
sensitivity for detection of several diarrheal pathogens. The TAC assay has undergone
extensive optimization and validation across international sites, as well as head-to-head
comparisons for pathogen-specific specificity and sensitivity compared to conventional
methods [16, 17]. Importantly, with the exception of ELISA for rotavirus detection,
conventional methods generally showed poor sensitivity and similar specificity compared
to TAC [16].

The TAC assay has limitations. Notably, near the TAC assay’s lower limit of detection
(Cq = 30-35) the odds ratios of pathogen detection in cases vs controls approaches 1 for
most pathogens, possibly indicating less clinically meaningful results at this end of the
detection range [16]. In this case, an odds ratio of 1 indicates no difference between cases
and controls, while an odds ratio < 1 suggests greater pathogen carriage in children
without overt diarrhea (controls). Additionally, with all pathogen targets assembled on a
single card, re-running a whole card for repeat tests of individual pathogens is relatively
expensive, and back-up conventional methods for single-pathogen repeats are necessary.
Finally, for labs without PCR capacity, substantial initial investment in a PCR platform is

7

required, though once established, TAC is less expensive per specimen compared to
running multiple conventional methods.

As applied to the GEMS and MAL-ED studies, TAC has illuminated two important
aspects of diarrheal disease previously obscured by conventional lab methods. First, due
to its high sensitivity (median 90.2% [IQR 84.2 – 95.1]), TAC detected a high prevalence
of enteric co-infections in both diarrheal and control specimens [16]. For example, in
GEMS, ≥ 2 pathogens were detected at diarrhea-associated Cq values in nearly 40% of
diarrheal stools (e.g. low Cq indicating high pathogen load with an odds ratio > 1 for
detection in cases vs controls). This finding revolutionizes our understanding of diarrheal
etiology, moving us past the model of single-pathogen diarrhea causation. Secondly,
analytic methods applied to TAC data suggest high levels of subclinical carriage of many
pathogens in controls based on the odds of pathogen presence in diarrheal vs control
specimens [10, 16].

These findings challenge the field to define a clinically-meaningful TAC Cq cut-off for
each pathogen that associates with diarrhea, and to grapple with the biologic relevance
and consequences of 1) multiple pathogens present at diarrhea-associated levels per stool
(how do we determine attribution?), and 2) the substantial prevalence of pathogenic
microbes found in children without overt diarrhea. Interpretation of TAC data and the
biologic implications of TAC findings is a work-in-progress, but this new tool has
already boosted our understanding of the complexity of diarrheal disease in the 21st
century.
8

1.4. Prevention of diarrhea
Armed with a better understanding of diarrheal etiology and the complex mix of coinfections in which pathogen exposure either does or does not lead to diarrhea, we turn to
the question of prevention. How do we leverage emerging knowledge and tools to
address the persistent burden of childhood diarrheal morbidity and mortality in LMICs?
Table 1.1. summarizes the current prevention (vaccines) and treatment options for the top
seven diarrhea-associated pathogens among infants in LMICs.
Table 1.1. Summary of prevention and treatment options for key pathogens
(immunocompetent infants)
Pathogen
Rotavirus

Pathogen
Class
Virus

Transmission route
Fecal-oral

Licensed
vaccine(s)?
Yes, with
18-61%
efficacy in
LMICs
No
No
No

Norovirus GII
Adenovirus 40/41
Campylobacter spp

Virus
Virus
Bacteria

Possibly respiratory
(limited evidence [18])
Fecal-oral
Fecal-oral
Fecal-oral

Shigella spp/EIEC

Bacteria

Fecal-oral

No

ST-ETEC

Bacteria

Fecal-oral

No

Cryptosporidium

Parasite

Fecal-oral
Zoonosis

No

Treatment options
ORS and zinc

ORS and zinc
ORS and zinc
ORS and zinc
Fluoroquinolone and
azithromycin, antibiotic
resistance is common
(severe disease only)
ORS and zinc
Fluoroquinolone and
azithromycin, antibiotic
resistance is common
ORS and zinc
Fluoroquinolones
ORS
Nitazoxanide

Abbreviations: spp=species; EIEC=Enteroinvasive Escherichia coli; ST-ETEC=Enterotoxigenic Escherichia coli;
ORS=oral rehydration solution.
Table compiled from pathogen-specific information available from the Centers for Disease Control and Prevention
(CDC) [19]

Our focus is on prevention of diarrhea, as opposed to treatment, particularly given the
limited treatment options against viral enteropathogens and the problematic development
of antimicrobial resistance against antibiotics for the leading causes of bacterial diarrhea
in LMICs (an issue beyond the scope of this inquiry), as indicated in Table 1.1..
9

1.5. Vaccines for diarrhea prevention
Rotavirus (RV) is the only leading diarrheal pathogen for which licensed vaccines are
currently available. Vaccine development for Shigella spp, ST-ETEC, Campylobacter,
and norovirus is ongoing, though no vaccine candidates are near licensure [14, 20].
Significant challenges to vaccine development remain for adenovirus 40/41 and
Cryptosporidium spp, and vaccines for these enteric pathogens are not under clinical
investigation.

1.5.1. Rotavirus vaccines
Given the high relative contribution of RV to diarrheal morbidity and mortality in
infancy, substantial efforts focused on RV vaccine development in the 1990s. To date,
five live, oral RV vaccines have been licensed, and two are pre-qualified by the WHO
and available in over 100 countries: Rotarix™ (RV1) and Rotateq® (RV5). Several other
live, oral RV vaccines are under development, as well as next generation inactivated
parenteral and subunit vaccines (subunit vaccines consist of viral protein fragments, as
opposed to whole virus) [21, 22].

In high-income countries (HICs), where RV was the leading cause of childhood diarrhea
prior to vaccine introduction in the mid-2000’s, RV1 and RV5 demonstrated efficacy
exceeding 95% against severe RV gastroenteritis [23, 24]. Following vaccine
introduction in the US in 2006, hospitalizations for RV decreased by up to 94%, and the
Centers for Disease Control and Prevention (CDC) reported up to 89.9% declines in
10

laboratory detection of RV compared to pre-vaccination years [25, 26]. Furthermore, cost
savings from reductions in health care utilization for RV gastroenteritis in the four years
following vaccine introduction (2007-2011) were estimated at $924 million. Vaccine
effectiveness studies have shown sustained protection against RV hospitalizations in
HICs using RV vaccines [27].

In contrast, efficacy and effectiveness of the same oral RV vaccines ranges from 18─61%
in LMICs, leaving a gap in vaccine protection against the highest-burden diarrheal
pathogen, for reasons that remain unclear [28-31]. Further complicating interpretation of
low vaccine efficacy, assessment of the standard immunogenicity measure for RV
vaccines, anti-RV IgA, has found mixed results for correlation with vaccine efficacy in
LMICs [32-35]. For example, RV vaccine efficacy trials in Malawi and South Africa
found only 43.6% of the vaccine group (treatment) effect explained by post-vaccination
RV IgA seropositivity [34]. Additionally, post-vaccination IgA seroconversion and
geometric mean concentrations among infants in countries with high child mortality rates
(LMICs) fall significantly below those of vaccinated infants in countries with low child
mortality (HICs): 53% vs 87% and 47 U/mL vs 236 U/mL respectively [35].
Determination of improved correlates of protection for RV is currently underway in our
research group.

Substantial research efforts by our team and others have aimed to identify factors that
explain RV vaccine underperformance in LMICs, including: maternal breast milk and
transplacental RV antibody inhibiting vaccine take [36-38]; delayed dosing of RV
11

vaccine to improve immune responses [39, 40]; RV strain diversity and homotypic vs
heterotypic vaccine protection [41]; RV seasonality and timing of vaccine dosing [42];
co-administration of oral polio vaccine and its effect on RV vaccine immunogenicity [43,
44]; and systemic inflammation association with reduced RV vaccine immunogenicity
[6]. Additional recent studies have found associations between histo-blood group antigen
polymorphisms (Lewis and secretor status) and risk of RV diarrhea, and microbiome
composition correlations with RV vaccine immunogenicity [45-48]. While these studies
offer insight into aspects of this complex problem, considerably more work must be done
to identify discrete factors that, collectively or individually, explain RV vaccine
performance.

Despite the remaining questions around RV vaccine efficacy in LMICs, the global
community, supported by the WHO and the Global Alliance for Vaccines and
Immunizations (GAVI), are proceeding with global roll-out of the currently licensed oral
RV vaccines on the premise that protection of ~50% is better than none, particularly in
countries with high diarrhea-attributable child mortality [49]. Given that RV is the
highest burden diarrheal pathogen in countries without the vaccines, vaccine roll-out can
be expected to have a substantial impact on diarrheal morbidity and mortality; however, a
significant gap remains in protection requiring consideration of complementary
interventions.

12

1.6. Non-vaccine diarrhea prevention measures
Given that RV is the only high-burden pathogen for which licensed vaccines are
available, as well as the efficacy issues with RV vaccines raised above, what other
preventive interventions may contribute to the goal of reducing childhood diarrheal
morbidity and mortality? Decades of public health research have tried to address this
question, with three interventions consistently mentioned in the literature on diarrhea
prevention: 1) household-level improvements in water, sanitation and hand washing; 2)
promotion of exclusive breastfeeding; and 3) micronutrient supplementation, specifically
zinc and vitamin A.

1.6.1. WASH interventions
The axiom that improved water, sanitation and handwashing (WASH) ameliorates
diarrheal burden has persisted; however, recent evidence challenges this canon. Pickering
et al found no difference in diarrhea prevalence in children from cluster-randomized
villages with and without a community-led total sanitation intervention [50]. Baker et al,
reporting on handwashing practices among caregivers in the GEMS study, found no
difference in the incidence of diarrhea among children whose caregivers washed their
hands with soap vs water and ash [51]. In the case of RV, the field has long rejected a
significant role for WASH in risk of RV diarrhea due to the ubiquitous prevalence of RV
in HICs with improved sanitation prior to vaccine introduction [18, 27]. We are awaiting
the results of the multi-site WASH Benefits trial enrolling a birth cohort of nearly 14,000
children in Kenya and Bangladesh with a primary outcome of diarrhea across six
randomization arms with different sets of WASH interventions [52]. Interesting
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hypotheses to pursue with next generation tools such as TAC would be whether the
effectiveness of WASH interventions is pathogen-specific, if there is greater impact on
bacterial diarrhea vs viral diarrhea, and whether success of WASH interventions
associates with inoculum size or pathogen mode of transmission (i.e. waterborne
transmission is more likely addressed by WASH interventions).

1.6.2. Promotion of exclusive breastfeeding
The benefits of exclusive breastfeeding (EBF) have been well characterized and reviewed
numerous times [53]. In short, infants, particularly in the first 6 months of life, have
immature and developing immune systems. During this period, breast milk not only
provides essential fats and micronutrients for survival and optimal growth, but also
transfers immune components, specifically IgA, to protect the infant during immune
maturation. As reviewed by Duijts et al, interventional and observational studies in high
income countries consistently found reduced risk of diarrheal disease with increased
duration of exclusive breastfeeding, often in a dose-dependent manner with each
additional month of exclusive breastfeeding [54]. Similar to other studies, results from
the Southhampton Women’s Survey showed a relative risk of diarrhea from birth to 6
months of RR 0.43 (95% CI 0.30–0.61) in infants breastfed for 6+ months vs those never
breastfed [55]. In LMICs with high levels of infectious disease exposure, breastfeeding is
critical for early protection from diarrheal (and other) pathogens.
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1.6.3. Micronutrient supplementation
Among micronutrients, deficiencies of zinc and vitamin A have been implicated for
association with increased diarrheal risk in the literature [3]. Among interventions for the
prevention of diarrhea, zinc prophylactic supplementation has shown positive results in
reducing the burden of diarrhea in LMICs [56-59]; however, clinical findings in
numerous trials have not elucidated a mechanism(s) by which zinc may affect diarrheal
risk, nor examined zinc associations with specific pathogens or class of pathogens. As
reported in Chapter 2, we found no correlation between vitamin A (measured as retinol
binding protein) and RV diarrhea in the PROVIDE Study; however infant serum zinc
level was inversely associated with risk of RV diarrhea.

1.7. The PROVIDE Study
From 2010-2014, we conducted the “Performance of Rotavirus and Oral Polio Vaccines
in Developing Countries” (PROVIDE) Study in a high-density urban slum in Dhaka,
Bangladesh to better understand why oral vaccines (rotavirus and polio) perform suboptimally in LMICs. The study’s central hypothesis was that failure of oral vaccines is
due to environmental enteric dysfunction (EED), a subclinical condition common in
LMICs characterized by gut barrier dysfunction, malabsorption and permeability of the
small intestine. The study design was 2x2 factorial with two interventional randomized
controlled trials (RCT): a RV vaccine efficacy trial, reported here and in Chapter 2 [60],
and a trial of the impact on mucosal immunity of an inactivated polio vaccine (IPV) boost
on the standard oral polio vaccine (OPV) series. Results of the polio trial are reported
elsewhere [61], and exploratory analysis of select biomarkers of EED and associations
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with vaccine performance in the first year of life are published [6]. We enrolled 700
infants in the first week of life and their mothers and followed them for two years.

With the 2013 WHO recommendation for global roll-out of RV vaccines into all national
immunization programs, PROVIDE was one of the last RCTs of RV vaccine efficacy in
the pre-vaccination era. To date, Bangladesh has not added RV vaccine to the national
program; however, GAVI has committed funding support for RV vaccine introduction,
which is scheduled to begin in 2018.

For the PROVIDE RV vaccine efficacy trial, infants were randomized 1:1 to receive RV1
or no RV1 on a delayed dosing schedule of 10 and 17 weeks (vs 6 and 10 weeks on the
standard WHO schedule). To better understand factors associated with RV vaccine
efficacy, we collected extensive socio-economic, clinical and biologic data, including
baseline household surveys, maternal surveys, comprehensive diarrhea surveillance,
feeding practices, regular anthropometry, cognitive function assessments, blood, diarrheal
and non-diarrheal stools, urine, saliva, and breast milk. Infants received all Bangladesh
national Expanded Programme on Immunization (EPI) vaccines through the study clinic,
which also provided free, high-quality primary care to both mothers and infants
throughout study participation. Detailed study methods are published [62].

As described in Chapter 2, in PROVIDE we found similar RV vaccine efficacy results
compared to other trials in LMICs: 51% (95% CI, 33.8%–63.7%) against RV diarrhea
(RVD) of any severity and 73.5% (95% CI, 45.8%–87.0%) against severe RVD in the
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per-protocol analysis [60]. We modeled risk of RV diarrhea using multivariable logistic
regression with 12 co-variates based on the literature and biologic plausibility, including
RV vaccine, socio-demographic and household variables, sex, breastfeeding, RV IgA
seroconversion and baseline infant health indicators (linear growth, retinol binding
protein, vitamin D and serum zinc).

In the final model, only lack of RV vaccine (OR 2.84, 95% CI 1.87–4.30) and serum zinc
status (OR 0.77, 95% CI 0.66─0.91) correlated with risk of RV diarrhea in the first year
of life: for every 10 µg/dL increase in serum zinc concentration (SZC), the odds of RV
diarrhea decreased 23%. No interaction was detected between SZC and RV vaccine; the
association between RV1 and RV diarrhea did not depend on zinc level (interaction term
p > 0.33). For severe RV diarrhea, only vaccination correlated with risk of disease.

Building on these results, Chapter 3 reports detailed analysis of the association between
zinc deficiency in the PROVIDE cohort and risk of pathogen-specific diarrhea, as well as
any viral diarrhea, using data from TAC analysis of PROVIDE diarrheal stool specimens.
Compared to the current literature, this is the most complete evaluation of the association
between zinc deficiency and specific pathogens to date.

In PROVIDE, 16.5% of the per-protocol infant population (N=577) were serum zinc
deficient at 18 weeks. These infants were 2.76 times more likely to have diarrhea in the
first year compared to zinc replete infants (OR 2.76, 95% CI 1.08 – 7.04), and zinc
deficient infants were nearly 4 times more likely to have viral diarrhea compared to non17

zinc deficient infants (OR 3.94, 95% CI 1.55 – 10.03). Furthermore, in Kaplan Meier
analysis, we found a strong correlation between zinc deficiency and time to first episode
of viral diarrhea, with median survival time of 27 weeks among zinc deficient infants
compared to 33 weeks in non-zinc deficient infants (p<0.0001). Infants with zinc
deficiency were at 58% greater risk of viral diarrhea compared to non-deficient infants
(HR 1.58, 95% CI 1.24 – 2.02).

The strength of these findings, combined with the results of our RV vaccine efficacy trial
(Chapter 2), led to an in-depth review of the zinc literature to better understand the clear
association between zinc deficiency and diarrhea, and to generate hypotheses to
interrogate the mechanism(s) of this association.

1.8. Zinc as an essential trace metal
Elemental zinc is essential to maintaining overall health and metabolism in humans as
well as plants, invertebrates, vertebrates and microbes. Known as a Type II nutrient due
to its ubiquitous roles, zinc catalyzes more than 300 metalloenzymes, anchors the
structural integrity of the genome, and regulates gene expression. Zinc also plays crucial
roles in cellular proliferation, differentiation and apoptosis, as well as in cell signaling,
response to infection, and inflammatory processes [56, 63-65].

1.9. Zinc bioavailability
The richest sources of zinc are animal products: shell fish, red meats, and dairy products
[66]. Zinc prolifically binds protein thereby facilitating zinc absorption in the intestines
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during protein digestion. High-protein diets are uncommon in LMICs where plant-based
diets are prevalent [67, 68]. In contrast to animal products, plant-based food sources are
high in phytate, especially legumes and grains, which are the mainstays of the
Bangladeshi diet (dal and rice). Phytate, the salt molecule of phytic acid found in plants,
binds both dietary and endogenous zinc, reducing zinc’s bioavailability, blocking
effective zinc absorption, and disrupting endogenous zinc homeostatic mechanisms [69].
While homeostatic regulation of zinc can cope with low zinc bioavailability in the
absence of phytate, there does not seem to be an adaptation in adult humans to increase
zinc absorption when faced with high phytate diets [70]. In this setting, reducing the ratio
of phytate to zinc in dietary intake, development and distribution of zinc-fortified foods,
fermentation to reduce phytate content in plant-based foods, or zinc supplementation are
the available options for addressing this physiologic limitation [56, 71, 72].

Interestingly, phytate inhibition of zinc absorption may be particular to adults. A
compelling modeling exercise incorporating data from 8 studies showed a lack of effect
of dietary phytate consumption on absorbed zinc among children aged 6 months – 13
years [73], a finding supported by several studies in diverse geographic locations [74-76].
The authors hypothesized that phytate is hydrolyzed in the upper gastrointestinal tract of
infants and children, who naturally have a higher stomach pH than adults, inducing
enzymatic activity aimed at degrading phytate during early digestion.

Relevant to this inquiry, the sole source of zinc nutrition for infants during EBF is from
breast milk. Poor zinc nutrition in infants during EBF therefore is either a result of
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insufficient zinc in breast milk or poor absorption of zinc in the infant. One recent study
in Thailand found correlations between zinc deficiency in infants and both maternal zinc
status and zinc levels in breast milk [77]; however the same result was not found in
several studies conducted 10 to 30+ years ago, as reviewed by Donangelo et al [78]. Zinc
levels in breast milk have been shown to be conserved, even under maternal zinc stress,
in a murine model, and one zinc supplementation trial of lactating human mothers
showed no effect of supplementation on breast milk zinc levels [79, 80]. A
comprehensive review by Brown et al concluded the most important determinant of
breast milk zinc concentration is length of time post-partum (with breast milk zinc
declining over time), as opposed to maternal zinc status [81].

Despite naturally declining zinc levels over the first 6 months post-partum, breast milk
continues to be an important source of zinc after cessation of EBF, particularly where
dietary zinc in complementary foods is suboptimal [81]. In the PROVIDE study, mean
duration of EBF was 17 weeks, short of the WHO-recommended 24 weeks, after which
the nutritional content in complementary foods becomes critical. In Bangladesh only 4045% of the recommended zinc intake for infants is met through breastfeeding plus typical
complementary foods [82].

1.10. Zinc homeostatic regulation
Given the intrinsic importance of zinc in a multitude of cellular processes, zinc in the
body is subject to tight homeostatic regulation. Zinc homeostasis is achieved through the
balancing effects of zinc absorption and excretion, which maintain zinc equilibrium
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across a broad range of dietary zinc intake levels. Both absorption and excretion take
place primarily in the intestines, with some urinary excretion, and both are responsive to
zinc status and changing physiologic needs [83, 84]. The highest rate of zinc absorption
in the small intestine takes place in the jejunum, but the greatest volume in the duodenum
[56]. Endogenous excretion of zinc into the intestinal lumen adjusts most rapidly to
changes in zinc intake, with marked decreases in excretion under conditions of low
dietary intake [85]. Zinc excretion occurs primarily via cellular release of zinc into the
intestinal lumen followed by fecal excretion.

In the setting of very low zinc intake, small zinc reserves in specific organs (liver, kidney,
spleen and pancreas) or minute cellular reserves in organelle compartments may be
tapped to maintain essential functions [56]. Bones hold approximately 30% of whole
body zinc, and bone reserves seem to provide a zinc reservoir during very low intake,
though the mechanism has not been characterized. It has been hypothesized that during
low intake, bones forego their usual uptake of zinc from the serum to sustain other tissues
(i.e. heart and muscles) [85].

Serum zinc level, which represents only approximately 1% of whole body zinc, is less
responsive to changes in dietary zinc intake, except at very low levels of zinc availability,
presumably to preserve circulating zinc for distribution to body tissues. Serum zinc
concentration (SZC) does, however, respond quickly to initiation and cessation of zinc
supplementation [86, 87]. Generally, clinical signs and symptoms of zinc deficiency are
not detectable in advance of a precipitous drop in SZC. (Note: Although plasma versus
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serum zinc concentrations (SZC) can differ slightly, likely due to differences in blood
processing, they are both considered valid measurements of zinc levels in individuals
[88].) Standard reference ranges for SZC, based on data from the National Health and
Nutrition Examination Survey (USA), are published [56, 89]. Reference ranges for
populations in LMICs are not available.

At the cellular level, zinc homeostasis is mediated by methallothionein (MT) and zinc
transporter proteins. Synthesis of MT, an intracellular zinc-binding protein discussed in
detail below, is upregulated in the setting of increased intracellular zinc (i.e. through
supplementation or dietary manipulation), as well as during acute phase responses,
inflammation and oxidative stress. Zinc also signals MT for degradation. Zinc
transporters have 2 distinct families: 14 Zrt- and Irt-like proteins (ZIP) import
extracellular zinc and zinc held in the lumen of cellular organelles into the cytoplasm,
and 9 known zinc transporter proteins (ZnT) move zinc from the cytoplasm into
organelles or export it across the plasma membrane [90].

1.11. Epidemiology and consequences of zinc deficiency
Zinc deficiency (ZD) is highly prevalent in LMICs with 17.3% of the world’s population
at risk [91]. Infants, children, and pregnant or lactating women have higher zinc
requirements, putting them at increased risk of ZD and its sequelae. The global
distribution of ZD resembles the geographic spread of highest risk for diarrheal morbidity
and mortality; South Asia and Africa are at greatest risk with an estimated 30% and 25%
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of the populations, respectively, consuming inadequate zinc. Among children under 5
years, 14.5% of diarrheal deaths in Asia and Africa are attributable to ZD [92].

Recent data from a cross-sectional study in Bangladesh showed an overall ZD prevalence
of 44.6% in children age 6-59 months, edging up to 51.7% among children sampled from
urban slums, like the PROVIDE population [68]. ZD prevalence in non-pregnant, nonlactating women age 15-49 was 57.3% nationally and 66.4% in slums, with an
astonishing 91% of women consuming inadequate dietary zinc to meet basic physiologic
needs. Pervasive high-phytate, low animal-source diets were reported across the socioeconomic spectrum, but with pronounced imbalance among the lowest income
participants. A separate study found a similar rate of ZD, 55%, in Bangladeshi women
during early pregnancy (mean gestation, 3.6 months) [93].

Consequences of zinc deficiency include increased susceptibility to infectious diseases
such as diarrhea, stunting, impaired cognitive development, and in extreme cases, severe
skin lesions [56, 89, 94]. Evidence from in vivo experiments of zinc restriction in adults
demonstrated extensive dysfunction of the immune system in zinc deficiency, including
dysregulated natural killer cell and TNF-α activity, thymic atrophy, aberrant lymphoid
hematopoiesis, dysregulated NF-κB signaling, reduced CD4+ T cell function, and
reduced immunoglobulin (Ig) responses [65, 95-99]. Zinc deficiency may disrupt the
structural integrity of enzymes critical to V(D)J recombinase events, such as recombinase
activating genes 1 and 2 (RAG1, RAG2), potentially limiting the repertoire of Ig’s and T
cell receptors and leading to increased susceptibility to infections [100-102]. From
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murine models, immunologic consequences of gestational zinc deficiency have been
suggested, with pups born from zinc-deprived dams exhibiting impaired humoral and
cell-mediated immune responses for up to three generations [103, 104].

1.11.1. Zinc deficiency and gut epithelial health and function
Strong evidence, from both animal and human models, indicates a role of zinc deficiency
in disrupting gut epithelial barrier function, which may have particular relevance to
diarrheal risk [99]. Chai et al conducted a compelling study in a porcine model in which
they demonstrated that piglets on a low zinc diet challenged with a porcine GI virus
exhibited significant small intestine villous atrophy and reduced jejunal surface area
compared to piglets on medium or high zinc diets with no post-challenge alteration in
epithelial structure [105]. Furthermore, piglets on the high zinc diet experienced
increased MT production and had higher and earlier antibody responses to viral challenge
compared to low zinc piglets.

The histologic changes described in low zinc piglets are consistent with environmental
enteric dysfunction (EED), a pathologic spectrum of structural and functional
abnormalities of the small intestine common in LMICs [106]. While the porcine study
showed zinc deficiency contributing to altered gut epithelium, the direction of this
relationship may not be straightforward. Evidence from a study among children in
Malawi concluded that EED disrupts zinc homeostasis by inhibiting zinc absorption in
the small intestine resulting in higher-than-expected fecal zinc excretion based on dietary
intake and physiologic requirements [107]. Lindenmayer et al describe the complex
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interplay between EED and zinc deficiency and develop a model of a vicious cycle in
which both conditions contribute to intestinal permeability and malabsorption in the
small intestine leading to immunologic dysregulation and increased susceptibility to
infections, particularly by diarrheal pathogens [108]. Attributing cause and effect in the
EED – zinc deficiency nexus, and its effect on risk of diarrhea in children, is complicated
and requires detailed interrogation of basic mechanisms as well as translational studies in
humans.

1.12. Possible mechanisms for the association of zinc deficiency and viral diarrhea
Findings from clinical research on zinc have contributed to characterizing the signs,
symptoms and consequences of zinc deficiency; however; research specifically designed
to test biologic pathways leading to increased risk of viral diarrhea is lacking. While
many questions remain unanswered, two intriguing areas for future mechanistic
investigation are highlighted here: dysregulated metallothionein transcription and
application of the concept of nutritional immunity to zinc regulation as an innate defense
against pathogens. Given the strong correlation found in PROVIDE between zinc
deficiency and specifically viral diarrhea (Chapter 3), as well as the limited treatment
options for viral diarrhea compared to other etiologies and the underperformance of
rotavirus vaccines, emphasis is placed on the relationship of these mechanisms to viruses.

1.12.1. Dysregulated metallothionein transcription in zinc deficiency
Metallothionein (MT) is a low molecular weight, intracellular, cysteine-rich metalbinding protein. A single MT protein can bind up to 7 zinc molecules, though MT has a
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higher affinity for cadmium and copper. Increased free zinc levels in the cytoplasm
induce metal regulatory transcription factor 1 (MTF-1) to initiate MT transcription [109111]. Strong evidence from porcine and murine models demonstrate MT transcription is
initiated by increased intracellular zinc as an acute phase response (APR) to infection or
injury (i.e. lung epithelial insult from mechanical ventilation), indicating a central role for
MT in regulating zinc homeostasis and mediating the APR [111-113].

Zinc deficiency has been shown to correlate with reduced MT expression [65, 113, 114].
One small study in humans (N=13) found, despite only a marginal decrease of 7% in
plasma zinc concentration on a 7-day zinc-restricted diet, mean MT level fell by 68% in
zinc-restricted human volunteers. By contrast, the same researchers found a 7-fold
increase in mean MT concentration from 40 ± 6 µg/g protein to 273 ± 85 µg/g protein
within 7 days on zinc supplementation (effect of supplementation on plasma zinc not
reported) [115]. Two additional small studies in humans corroborate these results,
particularly when measuring MT expression in monocytes [116, 117]. Due to its
sensitivity to whole-body zinc levels, MT has been suggested for evaluation as a
biomarker of zinc status [63].

Based on these findings, it would be particularly interesting to evaluate whether MT
expression differs in zinc deficient vs non-zinc deficient infants particularly during the
acute phase of viral diarrheal illness (i.e. Day 1 of a diarrheal episode), which could
illuminate critical pathways to preventing viral diarrheal disease.
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1.12.2. Zinc and nutritional immunity
The concept of “nutritional immunity” emerged out of the iron literature, but has since
expanded to examine the role of other essential trace metals, including zinc, in regulating
host response to pathogen presence as an innate defense against infection [118, 119].
Regarding zinc, substantial literature has described the role of nutritional immunity in the
clearance of bacterial infections, in which intracellular zinc accumulation, either for zinc
sequestration away from invading bacteria or zinc intoxication, particularly in
phagocytes, leads to bacterial death [120-123]. The rationale for the intoxication defense
involves the reliance of bacteria on zinc to support their own metabolic processes, similar
to humans, making bacteria vulnerable to zinc toxicity. Few studies have investigated
nutritional immunity as a defense strategy against viruses, which lack metabolic
functions. In this case, zinc sequestration away from intracellular viral pathogens, as
opposed to zinc accumulation for intoxication, may be the relevant nutritional immunity
defense strategy.

As described by Chaturvedi et al, zinc ions and zinc finger proteins (structural motifs
with 4 cysteines facilitating zinc-binding [56]) are intrinsic to many viruses and play
critical roles in viral transcription, replication, structural conformation and in counterdefense to host immune responses [124]. On the host side, evidence from one small
human study and one murine model showed increased MT expression specifically in
response to viral infections (hepatitis C and coxsackievirus) [125, 126]. Given its strong
binding affinity for zinc, increased intracellular MT would facilitate zinc sequestration by
binding labile zinc. This has not been examined for viral diarrheal pathogens; however,
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rotavirus provides a good model for consideration of how nutritional immunity may
mediate the host:virus interface in virus-infected cells.

Rotavirus is a triple-layered particle, which sheds its outmost layer of VP7 and VP4 upon
cell entry, exposing the VP6 layer. Rotavirions rely on zinc ions to anchor the structure of
the VP6 layer; however, the zinc recruitment strategy of rotavirus for this critical
conformational element has not been characterized [127, 128]. Rotavirus also relies on
zinc binding to interfere with host defense. Rotavirus non-structural protein 1 (NSP1) has
been identified as an E3 ubiquitin ligase depending on an N-terminal zinc-binding
domain to bind and target host interferon (IRF3) for proteasome degradation, thereby
disrupting the host’s immune response to rotavirus infection [129].

The importance of zinc in the “life cycle” of viruses suggests nutritional immunity, in this
case the MT-mediated sequestration of zinc away from pathogens in the intracellular
environment, may be important for clearance of viral infection. I hypothesize that
reduced MT expression, as demonstrated in zinc deficiency, inhibits innate nutritional
immunity against viral pathogens by reducing the cell’s ability to effectively sequester
zinc leaving labile intracellular zinc available for recruitment by viruses. Furthermore,
perhaps zinc supplementation in this context would promote adequate MT expression to
restore nutritional immunity sequestration functions and provide protection from viral
pathogens. These are areas for further investigation.
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Notably, the ability of MT to effectively utilize zinc in nutritional immunity may be
inhibited by heavy metal contamination. MT preferentially binds cadmium; however in
the absence of sufficient MT expression, as in zinc deficiency, cells become vulnerable to
cadmium toxicity, with consequences for zinc homeostasis [109, 130, 131]. This may be
particularly problematic in populations subjected to high levels of environmental heavy
metal contamination, such as in Bangladesh, and children may be at particularly high risk
for heavy metal toxicity [132, 133]. The relevance of heavy metal contamination,
particularly cadmium, to MT expression, zinc deficiency and risk of viral diarrhea
remains unstudied.

1.13. Zinc interventions: benefits and risks of supplementation
for diarrhea prevention
Finally, the potential for zinc supplementation interventions to positively impact diarrheal
morbidity and mortality in children in LMICs must be addressed, with consideration of
both infant and maternal supplementation strategies.

1.13.1. Infant supplementation
Several randomized clinical trials have found significant benefits of preventive zinc
supplementation in children in ameliorating the burden of diarrhea [58, 134-136];
however zinc supplementation is not a panacea. Some trials have not found an effect of
zinc supplementation on diarrheal prevalence or incidence, particularly among infants < 6
months [87, 137, 138]. Furthermore, open debate remains regarding appropriate dosage,
timing and delivery method for zinc supplementation, which may depend on the goal of
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supplementation: correcting the micronutrient deficiency vs preventing diarrhea
associated with low zinc [139-141].

On the vaccine front, Habib et al found no effect of zinc supplementation on oral polio
vaccine immunogenicity, even though they demonstrated a significant difference in zinc
levels between the intervention and control groups [142]. No similar study of the effect of
zinc supplementation on RV vaccine immunogenicity has been published. The only clear
effect of supplementation on vaccine response was in Bangladesh with a killed, subunit
oral cholera vaccine [143], though results of this trial showed mixed effects: while the
vibriocidal antibody response to vaccine was enhanced among zinc supplemented
children, the cholera-toxin antibody response was suppressed. Finally, it is worth noting
that many studies of zinc supplementation and vaccine response were conducted in HICs
where zinc deficiency is less prevalent and therefore supplementation may be less
effective in boosting vaccine responses.

1.13.2. Maternal supplementation
Evidence on the effects of maternal zinc supplementation on infant zinc status or diarrhea
is scant. Regarding maternal supplementation and reduced diarrheal morbidity in infants,
one double-blind, randomized controlled trial of maternal zinc supplementation (pre-natal
through neonatal) in Peru found significant reductions in total days with diarrhea and
incidence of diarrheal episodes lasting longer than 7 days among infants of supplemented
mothers [118]. Two additional studies, in Bangladesh and Indonesia, found similar
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benefits of maternal supplementation on infant diarrheal risk; this effect was only seen in
low-birth weight infants [144, 145].

Regarding maternal immunization, the limited data available showed no effect of zinc
supplementation during pregnancy on infant responses to BCG or Hib vaccines; no
results were reported for maternal immunization against diarrheal pathogens [146]. The
potential for maternal zinc supplementation to positively impact infant diarrheal burden
requires further investigation.

For breastfed infants, important questions include whether maternal zinc supplementation
improves zinc availability in breast milk and, if yes, whether this translates into improved
zinc status in infants. A detailed review of the literature by Donangelo and King
concluded the only consistently demonstrated effect of maternal zinc supplementation
during lactation has been a slower rate of decline in breast milk zinc concentration
compared to non-supplemented mothers [78]. No trials have tested whether zinc
supplementation of mothers during breastfeeding correlates with improved zinc status in
infants.

Perhaps the strongest role for mothers in diarrhea prevention is through continued
exclusive breastfeeding through the entire first six months of life. Public health programs
should continue to promote EBF, particularly in populations tending to cease EBF prior
to six months. The immunologic and nutritional benefits of EBF through six months
cannot be overstated. With the introduction of complementary foods, community
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education programs should emphasize locally-available and affordable options to ensure
adequate zinc nutrition throughout early childhood.

1.13.3. Risks of zinc supplementation
Risks associated with zinc supplementation are rare, but include nausea, vomiting and
diarrhea, and are usually seen only with zinc supplementation far exceeding the Tolerable
Upper Intake Level for extended periods [56, 141, 147].

1.14. Conclusions and future directions
The mandate to effectively curb the excess burden of childhood diarrhea in LMICs
persists as a top global public health priority in the 21st century. To reach the goal of
reducing diarrhea-associated child mortality from 4.1 per 1000 live births (2013) to 1 per
1000 live births by 2030, investments in new technology, clinical research and vaccine
science must continue. However, complementary interventions are required as the
research community continues to try to understand the challenges with vaccine
underperformance (rotavirus), accelerating the pace of vaccine development for enteric
diseases, and leveraging new technologies to increase our understanding of the complex
biologic pathways contributing to risk of death or disability due to diarrhea in early life.

Recent large-scale trials, including the PROVIDE Study, have clarified several important
insights into the etiology of diarrhea in LMICs and possible interventions for
ameliorating this burden. We now understand a single-pathogen model for diarrhea
causation is too simplistic. The TAC platform illuminated pervasive carriage of
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enteropathogens in both symptomatic children and children without diarrhea; the
implications of which are actively under investigation. What is the optimal strategy for
addressing the multiple co-pathogen burden, and how does this impact the efficacy of
pathogen-specific vaccines or other diarrheal interventions? These are open questions in
the field.

Among currently available interventions for diarrhea prevention, we have vaccines for
only one high-burden pathogen, rotavirus. While rotavirus vaccines have had a
tremendous impact, they leave a gap in protection, particularly against diarrheaattributable morbidity. WASH interventions have not consistently demonstrated efficacy
in preventing diarrhea, although the WASH Benefits Study may provide greater insight
into optimizing WASH interventions for this goal. Promotion of exclusive breastfeeding
(EBF) through 6 months and education on balanced complementary foods should
continue to receive attention, particularly in populations tending to stop EBF prior to 6
months and where traditional complementary foods offer sub-optimal nutrition.

The PROVIDE Study also provided evidence that infant zinc level plays a significant role
in risk of diarrhea, in particular from viruses, although this finding requires validation in
larger cohorts, possibly GEMS and MAL-ED. There is also significant geographic
overlap between risk of diarrhea and risk of zinc deficiency. However, many questions
remain regarding associations and mechanistic pathways between zinc and particularly
viral diarrhea that require synergistic, translational research to fully address.
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The role of zinc in pathogen propagation and infection remains understudied. From the
rotavirus model, we know zinc is intrinsic to the virus’ life cycle; the extent to which
other high-burden diarrheal pathogens rely on zinc and specifically how viruses recruit
and integrate zinc is uncharacterized. Does nutritional immunity with zinc extend to
viruses, and what are the underlying mechanisms of this evolutionary arms race between
host and pathogen? Does viral success in establishing infection relate to host
metallothionein (MT) levels and the ability of the host to sequester zinc away from viral
pathogens? Answers to these questions could elucidate mechanisms for focused
development of effective interventions to prevent the establishment of diarrheaassociated viral infections.

Clinical investigations (i.e. observational and case-control studies) are required to
determine whether MT transcription differs between zinc deficient and non-zinc deficient
infants, particularly during the acute phase of infection. If yes, how does this relate to
viral diarrheal risk? Can insufficient MT expression be corrected through zinc
supplementation? Specific to LMICs with high rates of environmental enteric dysfunction
(EED), untangling the cause-and-effect relationship between EED and zinc deficiency
may contribute to our understanding of the determinants of infant zinc status and how this
relates to viral diarrhea. Also relevant to many populations in LMICs, the role of heavy
metal contamination in MT function and zinc homeostasis as it relates to risk of viral
diarrhea requires further investigation with potential policy implications for affecting
clean water and environmental standards.
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Finally, carefully designed trials of zinc supplementation have the potential to determine
whether zinc, as a complementary intervention in both infants and mothers, may fill the
gap in protection against childhood diarrhea. In particular, zinc supplementation in
infants < 6 months is understudied, and appropriate preventive dosages, delivery methods
and timing of administration for optimal impact on viral diarrhea must be carefully
considered. Furthermore, it remains unclear whether maternal zinc supplementation
during lactation contributes to increased bioavailability of zinc in breast milk, and
whether this could affect protective differences in infant zinc status between
supplemented vs non-supplemented mothers. As future enteric vaccines become
available, and for the current rotavirus vaccines, there are no data on the effect of infant
or maternal zinc supplementation on infant vaccine outcomes, specifically in LMICs with
highest risk of diarrhea.

In conclusion, despite many unanswered questions, great progress has occurred and we
now have additional tools at our disposal to attempt to reduce the continued burden of
childhood diarrhea in the 21st century. This review delineates several key areas for future
investigation to solidify our understanding of diarrhea and expand the available set of
evidence-based interventions. The goals of elimination of childhood diarrheal mortality
and reduced morbidity are within reach and must be achieved.
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CHAPTER 2: DELAYED DOSING OF ORAL ROTAVIRUS VACCINE
DEMONSTRATES DECREASED RISK OF ROTAVIRUS GASTROENTERITIS
ASSOCIATED WITH SERUM ZINC: A RANDOMIZED CONTROLLED TRIAL
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2.2. Abstract
Background. Rotavirus is the world’s leading cause of childhood diarrheal death. Despite
successes, oral rotavirus vaccines are less effective in developing countries. In an urban
slum of Dhaka, we performed active diarrhea surveillance to evaluate monovalent G1P[8]
rotavirus vaccine (RV1) efficacy and understand variables contributing to risk of
rotavirus diarrhea (RVD).
Methods. We performed a randomized controlled trial of monovalent oral rotavirus
vaccine (RV1). Seven hundred healthy infants received RV1 or no RV1 (1:1) using
delayed dosing (10 and 17 weeks) and were followed for 1 year. Intensive diarrhea
surveillance was performed. The primary outcome was ≥1 episode of RVD. Nutritional,
socioeconomic, and immunologic factors were assessed by logistic regression bestsubsets analysis for association with risk of RVD and interactions with vaccine arm.
Results. Incidence of all RVD was 38.3 cases per 100 person-years. Per-protocol RV1
efficacy was 73.5% (95% confidence interval [CI], 45.8%–87.0%) against severe RVD
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and 51% (95% CI, 33.8%–63.7%) against all RVD. Serum zinc level (odds ratio [OR],
0.77; P = .002) and lack of rotavirus immunoglobulin A (IgA) seroconversion (OR, 1.95;
P = .018) were associated with risk of RVD, independent of vaccination status. Water
treatment and exclusive breastfeeding were of borderline significance. Factors not
associated with RVD included height for age at 10 weeks, vitamin D, retinol binding
protein, maternal education, household income, and sex.
Conclusions. In an urban slum with high incidence of RVD, the efficacy ofRV1 against
severe RVD was higher than anticipated in the setting of delayed dosing. Lower serum
zinc level and lack of IgA seroconversion were associated with increased risk of RVD
independent of vaccination.
Clinical Trials Registration. NCT01375647.
Keywords. rotavirus diarrhea; zinc; oral vaccine; underperformance; developing
countries.
2.3. Introduction
Rotavirus is the leading cause of child death from diarrhea. In 2008, prior to vaccine
introduction, rotavirus diarrhea (RVD) caused approximately 453 000 deaths, most in
South Asia and sub-Saharan Africa [1]. Three oral live attenuated rotavirus vaccines are
now licensed and having tremendous impact: the 3-dose pentavalent human-bovine
vaccine (RV5), the 2-dose monovalent G1P[8] vaccine (RV1), and the 3-dose human
bovine G9P[11] vaccine (116E). In phase 3 trials, RV5 and RV1 have robust efficacy of
>85% in high-income countries, as measured by protection from severe RVD or related
hospitalization [2, 3]. In contrast, efficacy is markedly lower in developing countries: in
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multiple clinical trials, oral rotavirus vaccine efficacy ranges from 18% to 61% in Africa
and Asia [4–7].

Although lower rotavirus vaccine efficacy in developing countries is well established,
little is understood about the biologic basis of vaccine underperformance. Previous efforts
have postulated mechanisms related to the vaccine itself, including dosing schedule and
inoculum, and factors impacting the child’s ability to respond to vaccination [8]. The
latter includes factors that prevent the vaccine from replicating in the intestine or blunt
infant immune responses, such as breast milk and maternal antibody interference,
enteropathy, and enteric coinfections [9–11]. Micronutrient deficiencies may also
contribute; zinc specifically plays an extensive role in host defense and gut health, and
deficiency has been associated with diarrheal morbidity and mortality [12, 13].

To assess factors related to RV1 performance, we enrolled a 700-child birth cohort in an
urban slum of Dhaka, Bangladesh, in the Performance of Rotavirus and Oral Polio
Vaccines in Developing Countries (PROVIDE) study: a randomized controlled trial of 2dose RV1 vaccine using a delayed dosing schedule at 10 and 17 weeks of age (compared
to the Expanded Programme on Immunization [EPI]–recommended schedule of 6 and 10
weeks). With a primary outcome of any RVD post-vaccination to 1 year, we conducted
biweekly home-based diarrhea surveillance for RVD. To inform public health
interventions and vaccine development efforts, we determined RV1 efficacy in this
population, assessed additional factors for associations with risk of RVD, and examined
possible interactions with the vaccine.
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2.4. Methods
2.4.1. Study design and participants
As part of the PROVIDE study, we performed a randomized, open-label, controlled trial
of live oral G1P[8] rotavirus vaccine (RV1) in a birth cohort of 700 children from the
Mirpur urban slum in Dhaka, Bangladesh. Infants meeting inclusion and exclusion
criteria were enrolled in the first week of life. Detailed study methods including
consenting and eligibility criteria, as well as results from PROVIDE on the association of
environmental enteropathy, enteric infection, and small intestinal bacterial overgrowth on
health outcomes, are published elsewhere [11, 14–16]. The study was approved by the
ethical review boards of the International Centre for Diarrhoeal Disease Research,
Bangladesh (icddr,b), the University of Vermont, and the University of Virginia. The
study was registered at Clinicaltrials.gov (NCT01375647).

2.4.2. Randomization and masking
Children were randomized using permuted blocks with random block size selection (4 or
8) and assigned to 1 of2 treatment groups: 50% (n = 350) to receive RV1 vaccine at
weeks 10 and 17, and 50% no rotavirus vaccine. All clinical investigators and
laboratories were masked to vaccine arm, but medical officers were not.

2.4.3. Procedures
The study was conducted from May 2011 through November 2013. Children were
enrolled from birth to age 7 days in the home by trained field research assistants,
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following comprehensive consenting procedures according to International Council on
Harmonisation Good Clinical Practice guidelines. Mothers were administered a baseline
survey at enrollment for demographics, household socioeconomic, water, and sanitation
data.

There were 10 clinic visits in the first year of life for anthropometry, phlebotomy, and
vaccinations [14]. Children received the Bangladesh EPI vaccines, including trivalent
oral polio vaccine at weeks 6, 10, and 14. All acute illnesses were evaluated by medical
officers, and RV1 dosing was delayed in children presenting with fever at scheduled
vaccination visits (n = 1). Breastfeeding was not withheld. Vaccine cold chain was
reviewed before administration. Children with severe malnutrition (weight-forage z score
< −3 SD) were referred for specialized care.

Complete diarrhea surveillance was conducted throughout the first year of life [14]. Field
research assistants visited households twice weekly to determine diarrheal episodes
through a structured questionnaire. Diarrhea was defined as ≥3 abnormally loose stools in
24 hours, per the mother, with distinct episodes separated by >72 hours diarrhea-free.
Severe diarrhea was defined as Vesikari score ≥11 [17]. One diarrheal stool sample was
collected during each episode. Mothers brought children into the clinic for further
assessment and treatment of diarrheal illness. Diarrheal stool specimens were tested for
rotavirus antigen by PosSpecT enzyme-linked immunosorbent assay (ELISA; Oxoid Ltd,
Hampshire, United Kingdom).
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Blood specimens for immunogenicity and micronutrients were collected at weeks 6 and
18 into trace-metal free Vacutainer tubes and cryovials (Grenier Bio-One and
ThermoScientific/Nunc, respectively). Plasma was evaluated for rotavirus-specific
immunoglobulin A (IgA) antibodies as described [18]. In brief, a capture enzyme
immunoassay (EIA) was performed using the rotavirus SA11 antigen; results were
expressed as units per milliliter determined by positive control reference serum.
Seropositive was defined as rotavirus IgA≥ 20 U/mL; seroconversion was defined as
seropositivity at week 18 following a seronegative result pre-vaccination (week 6).
Vitamin D and retinol binding protein were assessed using commercial ELISA kits
(Immunodiagnostics Systems Ltd, Tyne, United Kingdom and R&D Systems,
Minneapolis, Minnesota), and serum zinc was analyzed by flame atomic absorption
spectrophotometer using WinLab32 software.

2.4.4. Outcomes
The primary outcome for intention-to-treat (ITT) efficacy analysis was 1 or more
episodes of RVD from birth to 1year. RVD was defined as diarrhea positive for rotavirus
antigen by ELISA. Secondary outcomes were severe RVD, all-cause diarrhea (diarrhea of
any etiology) and all-cause severe diarrhea in the first year of life, and any and severe
RVD post-vaccination, from 18 to 52 weeks of age. Missed diarrheal stool specimens
were assumed negative for rotavirus. Rates of missingness are reported [14].
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2.4.5. Statistical analysis
The trial was designed with at least 90% power to detect 50% vaccine efficacy at α = .05,
assuming rotavirus infection in 26% of non-vaccinated children by 1 year. Primary
analysis was by ITT: all randomized subjects were included regardless of whether they
adhered to the protocol vaccine regimen or terminated study participation prior to 1 year.
Secondary per-protocol (PP) analyses were performed including all children who had 365
days of follow-up and, if assigned to the vaccine arm, received both doses of rotavirus
vaccine within the protocol-specified window.

Vaccine efficacy was calculated using the standard formula:
(ARUNVAX – ARVAX) / (ARUNVAX ×100), with ARVAX the attack rate in vaccinated and
ARUNVAX the attack rate in unvaccinated individuals. For dichotomous clinical outcomes,
proportions of children with diarrhea along with Wilson 95% confidence intervals (CIs)
and absolute risk differences in vaccinated and unvaccinated groups were calculated [19,
20].

Considering the study size and limitation on outcome events, a limited pool of 12
explanatory variables was selected a priori for analysis by best-subsets multivariable
logistic regression to determine a model for risk of RVD based on the literature, biologic
plausibility, and data availability. The best subset of p variables was chosen for the
minimum Mallows’ Cp statistic for which Cp < p [21]. From this main effects model, all
2-way interactions were tested by change in deviance from the reduced model (likelihood
ratio test). Model diagnostics included inspection of residuals, influential cases, and
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linearity in the logit for continuous variables. The Hosmer-Lemeshow goodness of fit test
was performed. Raw P values (Wald test) for regression coefficients were adjusted for
multiplicity post hoc using a stepdown Holm procedure [22]. The final model for RVD
was then applied to the clinical outcome of severe RVD. Analyses were performed using
SAS software version 9.3 (SAS Institute, Cary, North Carolina).

2.5. Results
2.5.1. Study population
After a community-wide survey of Mirpur, Dhaka, Bangladesh, 700 mother-child pairs
were consented and enrolled within 7 days of birth (median age, 5 days [range, 1–7
days]) (Figure 2.1.). Children were randomized to receive the 2-dose RV1 vaccine at 10
and 17 weeks of age or not. Population characteristics by randomization arm are shown
in Table 2.1.. There were no differences in characteristics between arms, except in
rotavirus IgA seroconversion (26.8% seroconverted among vaccinated vs 17.2% in
unvaccinated children; P = .005) and rotavirus IgA geometric mean titer (GMT) at week
18 (12.2 U/mL in vaccinated vs 4.3 U/mL in unvaccinated children; P = 2.4 × 10−8).
There were 92 dropouts, 12% (n = 43) in the RV1 arm and 14% (n = 49) in the control
arm (P = .53).
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Figure 2.1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
Abbreviation: RV1, monovalent G1P[8] rotavirus vaccine.
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Table 2.1. Characteristics by randomization arm
Randomization Arm
RV1 arm (n=350)

No RV1 arm (n=350)

Sex, male

182 (52.0)

186 (53.1)

Median age at enrollment, d

5 (1 – 7)

5 (1 – 7)

2.7 (1.7 – 4.1)

2.8 (1.9 – 4.0)

48.5 (43.1 – 55.4)

48.8 (44.5 – 54.6)

-0.98 (-3.54 – 2.67)

-0.89 (-4.36 – 1.69)

-0.91 (-4.53 – 1.83)

-0.86 (-3.61 – 1.40)

Exclusive breastfeeding at 18 wk

154 (50.0)

161 (53.5)

Home birth

100 (28.6)

81 (23.1)

24 (18 – 40)

24 (18 – 41)

Child features

Median weight at enrollment, kg
Median length at enrollment, cm
a

Median height-for-age z score at 10 wk

Median weight-for-age z score at 10 wk

a

b

Maternal features
Median age at enrollment, y

277 (79.1)

263 (75.1)

150 (137– 187)

150 (134 – 167)

Median post-partum weight, kgc

48.0 (30.2 – 80.0)

47.0 (30.0 – 77.0)

Other children ≤5 y old in home

92 (26.3)

96 (27.4)

Mother education class 9+

54 (15.4)

55 (15.7)

Median total monthly income, 1000 taka

10 (3 – 77)

10 (3 – 70)

Piped municipal water

339 (96.9)

339 (96.9)

Toilet or septic tank

195 (55.7)

172 (49.1)

One-room home

251 (71.7)

256 (73.1)

Median No. of household members

5 (1 – 16)

4 (2 – 18)

Any water treatment

209 (59.7)

211 (60.3)

80 (26.8)*

50 (17.2)*

12.2**

4.3**

Vaginal delivery
Median height, cmc

Household and Socioeconomic features

Immunogenicity
RV IgA seroconversion d
e

RV IgA geometric mean titer, U/mL
Serum Micronutrients at 18 weeks
Zinc, µg/dL f

75 (44 – 173)

77 (55 – 150)

Vitamin D, nmol/L g

58.8 (15.1 – 146.1)

58.1 (13.2 – 139.9)

Vitamin A, µg/ml g

26.1 (6.0 – 99.8)

25.8 (4.8 – 99.9)

Data are presented as No. (%) or median (range).
Abbreviations: IgA=immunoglobulin A; RV=rotavirus; RV1=monovalent G1P rotavirus vaccine.
a
N=318 RV1 arm, N=326 No RV1 arm
b
N=308 RV1 arm, N=301 No RV1 arm
c
N=330 RV1 arm, N=339 No RV1 arm
d
N=299 RV1 arm, N=291 No RV1 arm
e
N=289 RV1 arm, N=269 No RV1 arm
f
N=300 RV1 arm, N=301 No RV1 arm
g
N=305 RV1 arm, N=294 No RV1 arm
*P = 0.005, Chi-square test. ** P = 2.4 x 10-8
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2.5.2. Rotavirus diarrhea incidence and vaccine efficacy
Under intense surveillance, incidence of RVD in unvaccinated children in the densely
populated urban slum was 38.3 cases per 100 person-years, higher than previously
reported in developing countries [4, 5, 7] (Table 2.2.). In the primary analysis, vaccinated
children vs unvaccinated had significantly less RVD (19.1% vs 32.6%) and severe RVD
(4% vs 11.1%) in the first year of life (Table 2.3.). Overall, by ITT analysis, vaccine
efficacy was 41.2% (95% CI, 23.6%–54.8%) against all RVD and 64.1% (95% CI,
35.1%–80.1%) against severe RVD. The number of children needed to treat to prevent 1
case of RVD, derived as the reciprocal of the absolute risk difference, was 8 (95% CI, 6–
15). There were 3 cases of RVD and 2 cases of severe RVD between week 6, first dose of
the EPI-recommended RV1 dosing regimen, and week 10 when the first dose ofRV1 was
given in PROVIDE. Efficacy estimates against all-cause diarrhea were 1.3% (95% CI,
−4.8% to 7.1%) for any diarrhea and 12.7% (95% CI, −7.5% to 29.1%) for severe
diarrhea.
Table 2.2. Incidence of rotavirus diarrhea in “Performance of Rotavirus and Oral Polio Vaccines in
Developing Countries” Study compared with other cohorts
Rotavirus Diarrhea
Person
Cases (N)
Incidence a
Years

Severe Rotavirus Diarrhea
Person
Cases (N)
Incidence a
Years

PROVIDE (urban,
121
315.9
38.3
41
315.9
13
unvaccinated)
Rural Bangladesh and
109
1143.4
9.5
71
1156.9
6.1
Vietnam [4]
Sub-Saharan Africa [5]
294
2556.3
11.5
129
2585.9
5.0
South Africa and
NA
NA
NA
70
NA
8.0
Malawi [7]
Abbreviations: NA, not available; PROVIDE, Performance of Rotavirus and Oral Polio Vaccines in
Developing Countries study. a Incidence per 100 person-years.

PP analysis of efficacy post-vaccination (18–52 weeks) was performed. PP efficacy
against all RVD was 51%(95%CI, 33.8%–63.7%) and 73.5% (95% CI, 45.8%–87.0%)
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against severe RVD (Table 2.3.), while efficacy against any and severe all-cause diarrhea
was −3.1% (95% CI, −9.2% to 2.7%) and 22.1% (95% CI, −3.0% to 41.1%),
respectively.
Table 2.3. Rotavirus diarrhea incidence and vaccine efficacy, intention-to-treat and per-protocol
analyses

Abbreviations: CI, confidence interval; ITT, intention-to-treat; RR, relative risk; RV1, monovalent G1P[8]
rotavirus vaccine; RVD, rotavirus diarrhea.

2.5.3. Best subset of factors associated with rotavirus diarrhea and vaccine
interactions
There were 555 children with complete data for all 12 explanatory variables in the bestsubsets modeling of risk of RVD post-vaccination to 1 year. The explanatory variable
pool consisted of rotavirus vaccine arm, household income, sex, delivery status (cesarean
vs vaginal), mother’s education (below class 9 vs class 9 and above), household water
treatment (yes/no), exclusive breastfeeding at 18 weeks (yes/no), rotavirus IgA
seroconversion (IgA < 20 U/mL at 6 weeks and ≥20 U/mL at 18 weeks),
height-for-age z score (HAZ) at 10 weeks, and retinol binding protein, vitamin D, and
serum zinc at 18 weeks.
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In the multivariable best-subsets logistic regression analysis, the most parsimonious main
effects model (minimum Cp < p) was the 5-variable model including vaccination arm,
serum zinc, IgA seroconversion, exclusive breastfeeding, and water treatment. No 2-way
interactions were statistically significant; no variable impacted the effect of rotavirus
vaccine on risk of RVD (interactions with vaccine arm P > .33). The Hosmer-Lemeshow
goodness-of-fit test for the main effects model was performed (P = .67). Based on model
diagnostics, removing the 5 cases most poorly fit by the model (change in deviance P <
.005 with largest leverage) strengthened the odds ratio (OR) point estimates by
approximately 10% for vaccination arm, seroconversion, and serum zinc. There was no
expectation these cases were different from the study population, so results include all
cases.

Variables most strongly associated with risk of RVD were not receiving RV1 (OR, 2.84
[95% CI, 1.87–4.30]), serum zinc level (OR, 0.77 [95% CI, .66–.91]), and lack of IgA
seroconversion (OR, 1.95 [95% CI, 1.12–3.39]). Absence of water treatment and not
exclusively breastfeeding were also associated with increased risk of RVD (ORs of 1.50
and 1.46, respectively; Table 2.4.). The effects of RV1 and serum zinc retained statistical
significance after adjusting for multiple testing.

The final model selected for the RVD outcome was applied to severe RVD. Only lack of
vaccine was significantly associated with increased risk of severe RVD (OR, 3.81 [95%
CI, 1.78– 8.82]; P = .0008; Table 2.4.). The coefficients and effect size estimates for all
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variables were comparable to the all-severity RVD model, although cases of severe RVD
(incidence rate, 7.4%) were insufficient to meet statistical significance.

Table 2.4. Multivariable logistic regression main effects model for risk of rotavirus diarrhea and
severe rotavirus diarrhea

Variable

Coefficient
(SE)

Odds Ratio
(95% CI)

Main
effect raw
P value

Main
effect
adj. P
value

Rotavirus Diarrhea post week 18 in year 1
1.04 (0.68) 2.84 (1.87 – 4.30) 9.6 × 10–7 1.4 × 10–5
No RV1 arm (control)
-0.26 (0.08) 0.77 (0.66 – 0.91)
0.024
Zinc, 18 weeks (x 10ug/dL)
0.002
0.67 (0.28) 1.95 (1.12 – 3.39)
0.228
Lack of RV IgA seroconversion
0.018
0.40 (0.40) 1.50 (0.99 – 2.24)
0.612
Absence of water treatment
0.051
0.38
(0.20)
0.726
Stopped excl. breast feeding by week 18
1.46 (0.97 – 2.18)
0.066
Severe Rotavirus Diarrhea post week 18 in year 1
1.37 (0.39) 3.93 (1.83 – 8.47)
0.008
No RV1 arm (control)
0.0005
-0.12 (0.13) 0.88 (0.69 – 1.13)
1.000
Zinc, 18 weeks (x 10ug/dL)
0.325
0.59 (0.50) 1.81 (0.68 – 4.81)
1.000
Lack of RV IgA seroconversion
0.233
Absence of water treatment
0.54 (0.33) 1.72 (0.92 – 3.30)
0.099
1.000
0.47 (0.33) 1.59 (0.83 – 3.07)
1.000
Stopped excl. breast feeding by week 18
0.163
Raw P values from Wald test and adjusted using Holm stepdown procedure.
Abbreviations: CI, confidence interval; IgA, immunoglobulin A; RV, rotavirus; RV1, monovalent G1P[8]
rotavirus vaccine; SE, standard error.

2.6. Discussion
Using a clinical primary endpoint of RVD, we performed a controlled efficacy trial of
oral rotavirus vaccine given at 10 and 17 weeks after birth. The study was performed in a
highly rotavirus-endemic, densely populated, urban setting in Bangladesh. PP analysis
allowed comparison of our vaccine efficacy estimates with large phase 3 trials ofRV1 [4,
7]. Following a delayed dosing regimen, the efficacy of RV1 vaccine to prevent severe
RVD was 73.5% (95% CI, 45.8%–87.0%), higher than previously reported in developing
countries, including 45.7% efficacy against severe RVD in Bangladesh [4]. Vaccine
efficacy against RVD of any severity was 51% (95% CI, 33.8%–63.7%). Although past
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studies have suggested that rotavirus vaccine may protect against diarrhea from all
etiologies [2, 4], we saw no impact of rotavirus vaccination on all-cause diarrhea.

We postulate our improved efficacy was due to several factors in our study design.
Intense community-based diarrhea surveillance captured higher than expected incidence
of RVD (including mild cases not requiring medical attention). This high incidence
exposes the large burden of rotavirus disease and contributes toward higher vaccine
efficacy. Additionally, although not directly tested, our delayed dosing schedule at 10 and
17 weeks may have minimized maternal antibody interference with RV1 vaccine.
Although previous efficacy trials [4, 7] and immunogenicity studies [23, 24] have tested
2–3 doses of rotavirus vaccine administered between 6 and 16 weeks, this work is the
only efficacy trial with delayed dosing (10 and 17 weeks). An additional trial, using a
clinical endpoint to compare early vs late dosing schedules, would be necessary to
confirm superiority of delayed dosing. With only 5 cases of RVD between the currently
EPI-recommended start of vaccination (week 6) and week 10 (used here), the added risk
of delaying dosing appears minimal.

To further understand risk of RVD, we used multivariable best-subsets analysis to
evaluate factors for association with risk of RVD, including nutritional, socioeconomic,
hygiene, and immunologic variables. Beyond vaccination, only serum zinc and IgA
seroconversion were strongly associated with protection from RVD, and both were
independent of vaccination status. This suggests that, regardless of vaccine performance,
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improvement in these variables would decrease risk and overall burden of RVD. In the
final model, only vaccination and serum zinc level retained significance.

The observation that serum zinc is associated with decreased risk of RVD (OR, 0.77; P =
.002) recalls the importance of zinc in intestinal epithelial repair and immunologic
response mechanisms critical for mucosal protection [12, 25]. Previous studies have
demonstrated a clear benefit of both supplemental and therapeutic zinc in protection from
diarrheal disease in infants [13, 26]; however, there have been mixed results regarding
the benefits of zinc specifically in RVD [27, 28]. We did not find an association between
zinc and all-cause diarrhea.

Relevant to interpretation of our zinc findings, there has been controversy about the value
of serum zinc level as a biomarker of individual zinc status; however, the recently
published review of zinc under the National Institutes of Health’s Biomarkers of
Nutrition for Development (BOND) program [29] supports the use of serum zinc for this
purpose as it relates to clinical signs of zinc deficiency, is responsive to zinc
supplementation interventions, and can predict functional responses to supplementation,
particularly in populations where functional bioindicators (i.e., low HAZ scores) suggest
risk of zinc deficiency. With a stunting prevalence exceeding 20% by 1 year of age, the
PROVIDE cohort meets BOND’s recommended threshold for populations in which
serum zinc may be a particularly strong biomarker of zinc status, lending confidence to
the interpretation of our findings.

67

As in the PROVIDE study, a disconnect has been noted in several trials in developing
countries between development of rotavirus-specific IgA and vaccine efficacy [9];
however, our findings regarding immunologic responses raise concern. Less than onethird of PROVIDE children seroconverted following vaccination, and IgA GMTs were
markedly lower in PROVIDE, even compared to another cohort in Bangladesh that found
GMTs of47 U/mL among vaccinated children [30]. Importantly, immunogenicity in
PROVIDE was measured 1 week after the second dose of vaccine (week 18), whereas
other studies examined IgA 1–2 months after the second dose. Another possible
contributing factor may be the difference in antigenic lysate used in the capture EIA
assay in PROVIDE (rotavirus SA11 antigen) vs other studies.

Although not reaching statistical significance at the P ≤ .05 level, other potential risk
factors for RVD warrant further investigation in larger studies. Lack of exclusive
breastfeeding and absence of water treatment in particular, together with zinc
supplementation and vaccination, might be envisioned as the core of a focused diarrheaprevention public health plan offering both vaccination and improved baseline health to
reduce the burden of RVD.

Our work has several limitations. Although we performed intense diarrhea surveillance,
results may underreport the incidence of short-duration diarrheal episodes. We assumed
these episodes were negative for rotavirus, which may downwardly bias our efficacy
estimates. The Hawthorne effect, in which enrolled children receive higher-standard
primary care, may be present and upwardly bias efficacy estimates. Our sample size and
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number of outcome events limited the explanatory variables in our best-subsets analysis;
our results need confirmation in larger studies. Additionally, we measured postvaccination immunogenicity earlier than comparable trials. Although our results may
reflect poor primary response or poor boosting after the second dose of RV1, our data
could have underestimated immunogenicity based on this earlier time point.

Additional data are necessary to fully understand the limitations of oral vaccine efficacy
in developing countries and delineate the optimal response. Previously we described the
association of concurrent enteroviruses, as well as environmental enteropathy (measured
by fecal reg1B, neopterin, serum soluble CD14, and enteric infection), on RV1 failure
[11, 16]. Future work will focus on the impact of maternal antibodies and blood group
antigens, the role of enteric co-pathogens, the effect of zinc supplementation and whether
zinc has a pathogen-specific effect in protection from diarrheal disease, and the role of
asymptomatic infection in IgA seroconversion and rotavirus vaccine performance.
Research toward the identification of more predictive immune correlates of protection for
rotavirus is also under way (B. D. Kirkpatrick, personal communication). With high
efficacy against severe RVD, our work demonstrates the importance of oral rotavirus
vaccines in highly endemic settings and suggests that support of baseline health and
sanitation are still critical components of a public health approach, including vaccination,
to prevent morbidity and mortality due to rotavirus diarrhea.

69

REFERENCES
1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate
of worldwide rotavirus-associated mortality in children younger than 5 years before the
introduction ofuniversal rotavirus vaccination programmes: a systematic review and
meta-analysis. Lancet Infect Dis 2012; 12:136–41.
2. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy ofan
attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11–
22.
3. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human–
Bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23–33.
4. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against
severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised,
double-blind, placebo-controlled trial. Lancet 2010; 376:615–23.
5. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine
against severe rotavirus gastroenteritis in infants in developing countries in subSaharan
Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606–14.
6. Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent
human-bovine (116E) rotavirus vaccine in Indian children in the second year of life.
Vaccine 2014; 32(suppl 1):A110–6.
7. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe
diarrhea in African infants. N Engl J Med 2010; 362:289–98.
8. Neuzil KM, Zaman K, Victor JC. A proposed framework for evaluating and comparing
efficacy estimates in clinical trials of new rotavirus vaccines. Vaccine 2014; 32s1:A179–
84.
9. Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of
protection. Curr Opin Virol 2012; 2:419–25.
10. Babji S, Kang G. Rotavirus vaccination in developing countries. Curr Opin Virol
2012; 2:443–8.
11. Naylor C, Lu M, Haque R, et al. Environmental enteropathy, oral vaccine failure and
growth faltering in infants in Bangladesh. EBioMedicine 2015; 2:1759–66.
12. Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered
resistance to infection. Am J Clin Nutr 1998; 68(2 suppl):447S–63.

70

13. Bhutta ZA, Das JK, Walker N, et al. Interventions to address deaths from childhood
pneumonia and diarrhoea equitably: what works and at what cost? Lancet 2013;
381:1417–29.
14. Kirkpatrick BD, Colgate ER, Mychaleckyj JC, et al. The “Performance ofRotavirus
and Oral Polio Vaccines in Developing Countries” (PROVIDE) study: description of
methods of an interventional study designed to explore complex biologic problems. Am J
Trop Med Hyg 2015; 92:744–51.
15. Donowitz JR, Haque R, Kirkpatrick BD, et al. Small intestine bacterial overgrowth
and environmental enteropathy in Bangladeshi children. MBio 2016;7.
16. Taniuchi M, Platts-Mills JA, Begum S, et al. Impact of enterovirus and other enteric
pathogens on oral polio and rotavirus vaccine performance in Bangladeshi infants.
Vaccine 2016; 34:30680–75.
17. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores
for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259–67.
18. Azim T, Ahmad SM, Sefat EK, et al. Immune response of children who develop
persistent diarrhea following rotavirus infection. Clin Diagn Lab Immunol 1999; 6:690–
5.
19. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am
Stat Assoc 1927; 22:209–12.
20. Newcombe RG. Interval estimation for the difference between independent
proportions: comparison of eleven methods. Stat Med 1998; 17:873–90.
21. Akaike H. Information theory and an extension of the maximum likelihood principle.
In: 2nd International Symposium on Information Theory. Tsahkadsor, Armenia, USSR:
Akadémiai Kiadó, 1971:267–81.
22. Holm S. A simple sequentially rejective multiple test procedure. Scand Stat 1979;
6:65–70.
23. Ali SA, Kazi AM, Cortese MM, et al. Impact of different dosing schedules on the
immunogenicity of the human rotavirus vaccine in infants in Pakistan: a randomized trial.
J Infect Dis 2014; 210:1772–9.
24. Armah G, Lewis KD, Cortese MM, et al. A randomized controlled trial of the impact
of alternative dosing schedules on the immune response to human rotavirus vaccine in
rural Ghanaian infants. J Infect Dis 2016; 213:1678–85.

71

25. Haase H, Rink L. Functional significance of zinc-related signaling pathways in
immune cells. Annu Rev Nutr 2009; 29:133–52.
26. Aggarwal R, Sentz J, Miller MA. Role of zinc administration in prevention of
childhood diarrhea and respiratory illnesses: a meta-analysis. Pediatrics 2007; 119:1120–
30.
27. Dalgic N, Sancar M, Bayraktar B, Pullu M, Hasim O. Probiotic, zinc and lactosefree
formula in children with rotavirus diarrhea: are they effective? Pediatr Int 2011; 53:677–
82.
28. Patel AB, Dibley MJ, Mamtani M, Badhoniya N, Kulkarni H. Influence of zinc
supplementation in acute diarrhea differs by the isolated organism. Int J Pediatr 2010;
2010: 671587.
29. King JC, Brown KH, Gibson RS, et al. Biomarkers of Nutrition for Development
(BOND)—zinc review. J Nutr 2016; 146:858S–85.
30. Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. A systematic
review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus
vaccine efficacy. J Infect Dis 2013; 208:284–94.

72

CHAPTER 3: ZINC DEFICIENT INFANTS AT HIGH RISK OF VIRAL
DIARRHEA IN A BANGLADESHI BIRTH COHORT

3.1. Introduction
Diarrhea remains the second leading cause of child mortally globally. A significant
proportion of infectious diarrhea in infants is due to viral pathogens, which now can be
detected more readily with the use of quantitative multiplex PCR technologies [1].
Among all diarrheal pathogens, rotavirus (RV) accounts for the highest attributable
incidence of diarrheal disease and mortality in the first year of life [2]. Prevention of RV
and other viral diarrhea may be best addressed by vaccination. However, oral RV
vaccines consistently show sub-optimal efficacy of 18-61% in low and middle-income
countries (LMICs) with further evidence of waning effectiveness in year 2 [3-6], and no
vaccines are available for other leading viral diarrheal pathogens, specifically norovirus
and adenovirus 40/41. Furthermore, unlike bacterial infections for which antibiotics are a
treatment option, treatment of viral diarrhea is limited to oral rehydration solution and
zinc. A gap in protection against viral diarrhea exists in LMICs, and complimentary
strategies for diarrhea prevention are critical.

Zinc deficiency (ZD) is prevalent in LMICs with a high burden of RV and other diarrhea,
particularly South Asia and Sub-Saharan Africa [7, 8]. ZD has been linked to
dysregulation of biologic processes that may lead to increased risk of diarrhea, including:
poor gut epithelial repair and barrier function, immune and inflammatory dysfunction,
and aberrant microbiota composition [9-11]. Zinc deficiency in LMICs is complex. In
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these settings, children often are infected with multiple co-pathogens and experience high
rates of gut and systemic inflammation [12, 13], complicating interpretations of zinc
deficiency with zinc biomarkers responsive to acute-phase inflammatory processes [14].
Zinc deficiency in infants also may be tightly linked to maternal zinc nutrition, obscuring
the optimal target population for possible zinc interventions [15].

A significant body of evidence from LMICs demonstrates beneficial effects of zinc
interventions in children to treat diarrhea; however, less conclusive evidence from
randomized controlled trials is available for zinc in diarrhea prevention. One metaanalysis estimated preventive zinc supplementation of ≥ 3 months was associated with
14% reduction in diarrheal incidence (RR 0.86, 95% CI: 0.79–0.93) [16], while other
trials have not demonstrated an effect, particularly among infants < 6 months [17, 18].
Most trials of zinc supplementation have not distinguished diarrheal risks or responses
between children with vs without zinc deficiency at baseline.

In our past work evaluating rotavirus vaccines in Dhaka, Bangladesh (“Performance of
Rotavirus and Oral Polio Vaccines in Developing Countries” (PROVIDE) Study) [19,
20], we demonstrated that week 18 serum zinc concentration correlated with risk of
subsequent RV diarrhea from week 18–52 of life (OR 0.77, 95% CI (0.66-0.91),
independent of RV vaccination. This surprising correlation suggests focused
consideration of of zinc supplementation in populations at high risk of rotavirus diarrhea
to address the gap in vaccine protection.
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However, this observation also illustrates gaps in knowledge regarding the relationship
between infant zinc status and infectious diarrhea, which require better understanding to
guide the use of preventive zinc supplementation. Of interest, previous studies have not
assessed whether zinc is particularly effective against specific diarrheal pathogens, and
whether additional risk factors impact pathogen-specific diarrheal risk related to zinc
deficiency.

With the ultimate goal of optimizing preventive strategies against childhood diarrhea,
herein we seek to more comprehensively understand the important associations of zinc
deficiency and infectious diarrhea, and to evaluate co-factors including inflammatory
markers, breastfeeding practices, breast milk composition and demographics for possible
effects on the zinc-diarrhea relationship. Given the high burden of RV and other viral
pathogens in the first year of life, a unique relationship between higher zinc levels and
protection against viral diarrhea would support consideration of zinc interventions to
address the gap in protection against childhood diarrhea.

3.2. Methods
3.2.1. Study design and population
We conducted a formal randomized controlled trial of oral rotavirus vaccine efficacy
under the PROVIDE Study from May 2011 – November 2013 in a birth cohort of 700
infants in an urban, high-density, low-income section of Dhaka, Bangladesh, where
rotavirus vaccine is not routinely administered. Eligible infant-mother pairs were enrolled
in the first week post-partum following consent of the mother, and infants were
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randomized 1:1 to receive oral Rotarix™ vaccine (RV1) or no RV1 at weeks 10 and 17.
Infants were followed for one year in the RV1 trial. Detailed eligibility criteria and
consenting and randomizations procedures are described elsewhere [19, 20]. The study
was conducted per Good Clinical Practice guidelines, and the study was approved by
ethical review boards at the International Centre for Diarrhoeal Disease Research,
Bangladesh (icddr,b) and the Universities of Vermont and Virginia. Clinicaltrials.gov
registration is NCT01375647.

3.2.2. Clinical procedures
Mothers’ study participation included completing detailed questionnaires on household
demographics, water and sanitation, socioeconomic status, and personal reproductive
history, as well as breast milk specimen collection within 6 weeks of enrollment. Infants
were scheduled for 10 study visits in one year for receipt of routine childhood
immunizations (per Bangladesh’s national program) and RV1 vaccine, anthropometry
and blood draws. Interim clinic visits for acute illness and diarrheal assessments occurred
as needed. All acute care treatments prescribed through the study clinic were recorded.

Active, community-based diarrhea surveillance consisted of twice weekly home visits by
trained Field Research Assistants to capture infants’ history of diarrhea, fever, and
vomiting, home use of antibiotics and oral rehydration solution, and breastfeeding
practices. Infants with diarrhea were referred to the study clinic for assessment. Mothers
or study field assistants collected one diarrheal specimen per episode, defined as ≥ 3
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loose stools in 24 hours per the mother with three diarrhea-free days distinguishing
episodes.

3.2.3. Laboratory procedures
Each diarrheal specimen was analyzed by quantitative real-time PCR, TaqMan Array
Card (TAC), for 35 enteropathogen targets. Detailed methods for development, validation
and optimization of the TAC assay have been published [21-23]. Briefly, QIAamp Fast
DNA Stool mini kits were used for nucleic acid extractions, which were then run in
individual pathogen-specific probe-based assays compiled on a single card, including two
external controls. The assay read-out was a Quantification Cycle (Cq) value, representing
the amplification cycle number at which flouresced pathogen-specific nucleic acid was
detectable above background, with a positive range of 0 < Cq < 35.

For this analysis, the top seven pathogens identified in previous studies for diarrhea
attributable incidence in the first year of life in LMICs were selected from the TAC
panel: rotavirus, adenovirus 40/41, norovirus, Campylobacter jejuni, Shigella
spp/enteroinvasive E. coli (EIEC), heat-stable enterotoxigenic E. coli (ST-ETEC), and
Cryptosporidium spp [1, 24, 25]. Non-polio enterovirus (NPEV) was also included based
on previously reported high prevalence of NPEV infection in the PROVIDE cohort [26].
Published diarrhea-associated TAC Cq cut-offs for each pathogen were applied for
assigning pathogen etiology in diarrheal specimens; extensive methods for determining
diarrhea-associated TAC Cq’s are described elsewhere [1, 21, 23, 25, 27]. No diarrheaassociated Cq threshold has been defined for NPEV, Cq < 35 was used.
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Blood specimens for serum zinc concentration (SZC) and acute phase inflammatory
markers interleukin-6 (IL-6) and C-reactive protein (CRP) were collected at week 18 in
trace metal-free Vacutainer tubes and cryovials (Grenier Bio-One and
ThermoScientific/Nunc). Specimens were centrifuged and 25-30 μL of serum aliquoted
for SZC measurement and stored at < -70ᵒ C for 4 to 28 months prior to analysis by flame
atomic absorption spectrophotometer usingWinLab32 software. Zinc deficiency was
defined as SZC < 65μg/dL based on suggested SZC cut-offs from the BOND Zinc Expert
Panel Review and sensitivity analysis in the PROVIDE dataset [28]. Serum IL-6 was
analyzed by BioRad’s 17-plex Bio-Plex Cytokine Assay kit (Cat # M50-00031YV).
Serum CRP was assessed by ALPCO ELISA kit assay per the manufacturer’s instructions
(Cat # K-9710s).

Detailed methods for breast milk specimen collection, processing and analysis are
published [29]. Briefly, within six weeks of enrollment specimens were expressed
directly into 5mL falcon tubes at the mother’s convenience after instruction on manual
expressing by field staff. Samples were collected from mothers and transported to the
icddr,b laboratory at 4ᵒ C where dried milk spot cards were prepared with 50μL breast
milk and anti-oxidant pre-treatment prior to shipping to OmegaQuant Analytics, Sioux
Falls, SD. The cards were analyzed by gas chromatography for 26 breast milk fatty acids,
including linoleic acid (LA) and dihomo-γ-linoleic acid (DGLA). The ratio of LA:DGLA
in breast milk was included as a potential marker of maternal zinc status [30, 31].
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3.2.4. Statistical analysis
Frequencies for select enteropathogens in diarrheal specimens were determined as total
number of pathogen-specific positive TAC results (0 < Cq < diarrhea-associated Cq cutoff) over total number of evaluated stools (N=1,367). Incidence per infant was calculated
as ≥ 1 pathogen-specific episode of diarrhea from weeks 18-52, using the same diarrheaassociated Cq cut offs. Diarrheal stools or episodes with more than one select pathogen
present at diarrhea-associated levels were counted for each pathogen(s). Infants were
excluded from pathogen-specific analysis if they had missing stools plus only negative
TAC results for a pathogen in evaluated stools. Infants with a positive TAC result in any
evaluated stool were included in analysis for the detected pathogen(s), regardless of
missing stools.

The primary analysis was a set of independent univariate logistic regression models each
with an outcome of proportion of infants with incidence of ≥ 1 pathogen-specific
diarrheal episode from week 18-52 and zinc deficiency (yes vs no) as predictor. To
control for infections or inflammatory processes coinciding with the week 18 SZC
measurement that may have effected SZC [14], acute phase pro-inflammatory markers
IL-6 and CRP at week 18 were tested for possible confounding on the relationship
between SZC and diarrheal outcomes. Spearman’s correlation was used to determine
relationships between IL-6 and CRP with SZC (continuous). IL-6 and CRP were assessed
for confounding in bivariate and multivariable models by > 10% change in the zinc beta
coefficient over the primary models, and model fit was assessed by Akaike information
criterion (AIC) [32].
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Given high rates of co-infection with multiple pathogens per diarrheal specimen,
including at diarrhea-associated TAC Cq’s as well as sub-clinical carriage (TAC Cq >
diarrhea-associated cut off), co-pathogen burden in rotavirus positive stools was
evaluated to determine whether SZC at week 18 differed between specific combinations
of co-pathogens. The Mann-Whitney test compared mean week 18 SZC in infants with
rotavirus positive diarrhea plus vs minus individual co-pathogens, determined by
presence or absence of each select enteropathogen at any positive Cq value, 0 < Cq < 35,
in rotavirus diarrheal stools.

Kaplan-Meier (KM) time-to-event analysis compared time to first viral diarrhea in zinc
deficient vs not deficient infants, assessed for each virus separately and any viral
diarrhea. Infants with no viral diarrhea detected from week 18-52 were censored at Day
365. Cox proportional hazards modeling was used to assess candidate confounders of the
KM time series results, applying the same assessment criteria described above for
multivariable logistic regression models. Candidate confounders for the Cox proportional
hazards model were tested for association with zinc deficiency by Chi Square for
dichotomous predictors and Wilcoxon Rank Sum for continuous predictors.

Analyses were performed in SAS software version 9.3 (SAS Institute, Cary, North
Carolina).
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3.3. Results
3.3.1. Diarrhea and zinc descriptive data
Out of 700 infants enrolled in PROVIDE, 608 completed one year of follow up per
protocol contributing 1,773 reported diarrheal episodes between weeks 18 and 52.
Diarrheal specimens were collected for 1,434 episodes (81%). The majority of missed
specimens were from short duration episodes lasting 1-2 days. 88% (N=535) of infants
had zero or only one missing specimen. Of the collected specimens, 1,367 (95%) were
evaluable by TAC.

As shown in Table 3.1., non-polio enterovirus (NPEV) and adenovirus 40/41 were the
most prevalent pathogens in diarrheal stools and had the highest incidence in infants,
although positive results for NPEV were based on TAC Cq < 35 in the absence of a
published (and perhaps lower) diarrhea-associated cut-off. Of note, rotavirus accounted
for the highest attributable incidence of diarrhea in the first year of life in PROVIDE
based on attributable fraction calculation [1, 33]. High rates of sub-clinical carriage were
detected for several pathogens, in particular norovirus, Campylobacter jejuni, and STETEC, which were detected in diarrheal stools but at > diarrhea-associated Cq’s in 13%,
26% and 18% of stools respectively, in addition to the prevalences reported in Table 3.1..
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Table 3.1. Prevalence and incidence of pathogen-specific diarrhea, weeks 18–52
Pathogen prevalence
(% positive in 1,367
diarrheal stools)a

Percent of infants
with ≥ 1 pathogen-specific
diarrheal episode (N=608)a

Rotavirus (35)
Norovirus (27.6)
Adenovirus 40/41 (35)
Non-polio enterovirus (35b)
Any viral diarrhea
Campylobacter jejuni (19.7)
Shigella spp/EIEC (33.1)

19.9
12.7
39.9
47.9
78.5
3.4
11.1

47.6
34.7
66.0
69.4
82.2
11.0
29.5

ST-ETEC (26.2)
Any bacterial diarrhea
Cryptosporidium (29.1)

11.9
23.1
6.0

33.3
51.1
15.5

Pathogen (diarrhea-associated Cq)

a

Columns sum to > 100% due to co-pathogens
published diarrhea-associated Cq cut-off; 0<Cq<35 used to determine positive stools.
Abbreviations: spp=species; EIEC=Enteroinvasive Escherichia coli; ST-ETEC=Enterotoxigenic Escherichia coli

b No

At week 18, 577 infants had serum zinc concentration (SZC) measurements. 16.5% of the
cohort (N=95) was at or below the threshold for zinc deficiency at week 18. The range of
SZC was 44–173μg/dL, with a mean of 77μg/dL and median of 76μg/dL. Table 3.2.
summarizes population characteristics for key variables, comparing infants with vs
without zinc deficiency.
Table 3.2. Key variables in infants with vs without zinc deficiency
Zinc deficient
Non-zinc deficient
infants
infants
Sex (% female)
36.8
50.2
Lack of exclusive breast feeding at week 18 (%)
52.6
50.8
Lack of household water treatment (%)
44.2
38.2
Birth delivery method (% cesarean)
25.3
23.2
Any pre-week 18 diarrhea (%)
63
61
Week 18 IL-6 inflammatory markera
64.0 (83.8)
50.5 (104.5)
Week 18 CRP inflammatory markera
5.8 (12.2)
2.5 (6.4)
LA:DGLA in breast milka
20.0 (10.8)
22.0 (10.0)
a
Mean (SD). Wilcoxon Rank Sum P-values based on log transformed data.
All other P-values from Chi Square.
Variable
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P-value
0.02
0.75
0.27
0.67
0.66
0.0003
0.01
0.004

3.3.2. Logistic models for diarrheal outcomes and zinc deficiency
Univariate logistic regression models tested the association between zinc deficiency and
pathogen-specific diarrheal outcomes. As shown in Figure 3.1., the odds ratio point
estimates and confidence intervals for each viral pathogen were similar, with increased
odds among zinc deficient vs non-deficient infants for rotavirus OR 1.67 (95% CI 0.99 –
2.83), norovirus OR 1.74 (95% CI 1.01 – 3.01) and adenovirus OR 1.64 (95% CI 0.94 –
2.86). The odds of NPEV diarrhea among zinc deficient infants was highest OR 2.34
(95% CI 1.24 – 4.41).

Grouping viral pathogens into any viral diarrhea, zinc deficient infants had nearly four
times higher odds of viral diarrhea compared to non-zinc deficient infants, OR 3.94 (95%
CI 1.55 – 10.03, p=0.004), see Figure 3.1.. The wide confidence interval for any viral
diarrhea was likely due the low frequency of zinc deficient infants with no viral diarrhea
(6%). Zinc deficiency was associated with having any diarrhea OR 2.76 (95% CI 1.08 –
7.04), regardless of etiology. Zinc deficiency did not associate with pathogen-specific
bacterial or parasitic diarrheal outcomes.

Both inflammatory biomarkers, IL-6 and CRP, correlated with zinc deficiency at week 18
(Table 3.2.); however, neither independently associated with pathogen-specific diarrheal
outcomes or any viral diarrhea in univariate tests. Inclusion of IL-6 in multivariable
models did, however, improve model fit and change the zinc beta coefficients by > 10%
for any viral diarrhea, as well as most individual pathogens. IL-6-adjusted point estimates
and confidence intervals are shown in Figure 3.1..
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Figure 3.1. Odds ratios with 95% CI for univariate diarrheal outcomes in infants zinc deficient vs
non-deficient at week 18
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3.3.3. Kaplan-Meier analysis and Cox proportional hazards
Figure 3.2. Kaplan-Meier curves for time to first episode of diarrhea weeks 18–52 in infants zinc
deficient vs non-deficient at week 18
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To determine whether zinc deficient infants were at risk for viral diarrheas earlier in the
first year of life compared to non-zinc deficient, Kaplan-Meier analyses were done for
each viral pathogen, as well as any viral diarrhea. On time-to-event curves, a strong
correlation was found between zinc deficiency and time to first episode of any viral
diarrhea, with median time diarrhea-free of 27 weeks in zinc deficient infants vs. 33
weeks in non-deficient infants (p<0.0001). At the individual pathogen level, significant
associations were seen between zinc deficiency and shortened time to rotavirus (log rank
p=0.05) and NPEV diarrhea (log rank p<0.001), with no significant difference at p≤0.05
for adenovirus or norovirus diarrhea (p=0.12 and p=0.08 respectively). Kaplan-Meier
curves for any viral diarrhea, rotavirus and NPEV are shown in Figure 3.2..

Given strong correlations found throughout the analyses between zinc deficiency and any
viral diarrhea, Cox proportional hazards modeling focused on this outcome. Eight
potential risk factors were assessed for association with time to first viral diarrhea, Table
3.3.. Adding these step-wise into a multivariable model resulted in the most parsimonious
proportional hazards model including zinc deficiency, infant’s sex, lack of household
water treatment, LA:DGLA ratio in mother’s breast milk, and lack of exclusive
breastfeeding at week 18. In the final model, zinc deficient infants were at 45% greater
risk of viral diarrhea compared to non-deficient infants (HR 1.45, 95% CI 1.13–1.87,
p=0.003) with evidence of confounding due primarily to the addition of LA:DGLA to the
model (18% change in zinc beta coefficient over univariate zinc model). Females had
reduced risk of viral diarrhea compared to males (HR 0.84, 95% CI 0.69 – 1.02), and the
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effect sizes for lack of both exclusive breastfeeding and household water treatment were
very similar (HR 1.20, 95% CI 0.98─1.45 and 1.46 respectively).
Table 3.3. Cox proportional hazards model with candidate confounders of association between week
18 zinc deficiency and time to first viral diarrhea, week 18-52
Variable

Hazard ratio (95% CI)
Univariate Hazards Ratios (main effect p-values)
Zinc deficient at week 18
1.58 (1.24 – 2.02)
Sex (female)
0.79 (0.65 – 0.96)
No household water treatment
1.25 (1.03 – 1.53)
LA:DGLA (log, continuous)
0.78 (0.62 – 0.98)
Lack of exclusive breast feeding at week 18
1.23 (1.02 – 1.50)
Birth delivery method (cesarean)
0.85 (0.67 – 1.07)
Week 18 IL-6 (log, continuous)
1.05 (0.98 – 1.13)
No rotavirus vaccine
1.07 (0.89 – 1.30)
Multivariable Model (adjusted p-values)
Zinc deficient at week 18
1.45 (1.13 – 1.87)
Sex (female)
0.83 (0.68 – 1.01)
No household water treatment
1.20 (0.98 – 1.46)
LA:DGLA (per standard deviation of log, continuous)
0.93 (0.84 – 1.02)
Lack of exclusive breast feeding at week 18
1.20 (0.98 – 1.45)

P-value
0.0003
0.02
0.02
0.03
0.03
0.16
0.20
0.47
0.003
0.06
0.08
0.13
0.07

3.3.4. Co-pathogens
PROVIDE infants had a mean of 2.74 enteropathogens detected per diarrheal stool
(range, 0-9 pathogens per stool at any positive Cq value). Although rotavirus (RV) was
considered diarrhea-causing when present, 95% of RV positive stools were co-infected.
The highest rates of co-infection were with other viruses: 40% with NPEV, 38% with
adenovirus and 12% with norovirus, as compared to 4% – 12.5% co-infection with
bacterial or parasitic pathogens. Despite high rates of co-infection, there was no
difference in mean week 18 SZC between infants who had RV diarrhea +/- co-infection
with other pathogens (all p-values for paired comparisons > 0.20, Mann-Whitney test,
data not shown). Separate exploratory analyses showed pervasive carriage of non-STETEC E. coli spp, particularly enteroaggregative E. coli (EAEC), which was detected in
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68% of all diarrheal stools, nearly 80% of infants, and co-infected with 71% of RV
diarrheal stools.

3.4. Discussion
Previous work from the PROVIDE Study suggested a relationship between serum zinc
concentration (SZC) and risk of rotavirus diarrhea in the first year of life [19]. Here, we
have shown a broader association with a significant relationship between infant zinc
deficiency at week 18 and risk of any viral diarrhea up to one year. While the association
appears not to be specific to rotavirus, the trends of similar risks across viruses in the
state of zinc deficiency may suggest a common mechanism for the protective effect of
zinc against viral diarrhea. The association of SZC with any diarrhea in the first year also
is likely driven by the high prevalence of viruses in the cohort: for diarrheal attributable
incidence, five out of the top 6 diarrheal pathogens in PROVIDE are viruses [33]. These
findings have particular importance for populations in LMICs affected by high rates of
zinc deficiency and heavy childhood diarrheal burdens in the setting of moderate
rotavirus vaccine efficacy and no vaccines for other viral diarrheal pathogens.

Given that breast milk is the sole source of zinc nutrition for most infants in the first
months of life, understanding the role of maternal zinc nutrition is critical to optimizing
zinc interventions for diarrhea prevention. The extent to which zinc deficiency in mothers
translates into zinc insufficiency in breast milk is unclear; however, associations have
been shown between maternal plasma zinc and breast milk zinc concentration, as well as
between maternal and infant plasma zinc [15]. Furthermore, consequences of maternal
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zinc deficiency during gestation have been shown to persist for three generations of
offspring [34]. While we did not directly measure mothers’ zinc, we measured the breast
milk fatty acid ratio of linoleic acid to dihomo-γ-linoleic acid (LA:DGLA). This ratio,
when measured in erythrocytes, correlates with individual zinc status [30, 31]. We have
not found literature demonstrating a similar association in breast milk, however, to the
extent this association may be found, we could hypothesize that reduced breast milk
LA:DGLA may indicate maternal zinc deficiency which in turn may negatively impact
zinc nutrition in infants, contributing to increased risk of viral diarrhea. The confounding
effect shown here of LA:DGLA on the association of infant zinc deficiency with earlier
viral diarrhea supports further investigation of this hypothesis.

Once infants cease exclusive breastfeeding (EBF), other factors become important in both
zinc nutrition and diarrheal pathogen exposures. We found infants not exclusively
breastfed by week 18 were at significantly higher risk of earlier viral diarrhea. Only
approximately half the PROVIDE cohort maintained EBF through week 18 [19], which
may be particularly problematic in Bangladesh where only 40-45% of the recommended
zinc intake for infants is met through breastfeeding plus typical complementary foods
[35]. A longer duration of EBF in this context has greater potential to meet infants’ zinc
requirements [36], perhaps affording better protection against viral diarrhea through the
first year of life. Lack of household water treatment also correlated with earlier viral
diarrhea; household-level interventions of water purification methods may improve
diarrhea-related outcomes.
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In terms of biologic mechanisms, zinc deficiency has been linked to dysregulated
metabolic processes that may lead to increased risk of viral diarrhea, in particular poor
gut epithelial repair and barrier functions. In a clear example, Chai et al (2014)
demonstrated that piglets on a low zinc diet challenged with a porcine GI virus exhibited
significant small intestine villous atrophy and reduced jejunal surface area compared to
piglets on medium or high zinc diets with no post-challenge alteration in epithelial
structure [9]. The histologic changes described in low-zinc piglets are consistent with
environmental enteric dysfunction (EED), a pathologic spectrum of structural and
functional abnormalities of the small intestine common in LMICs. Given the high copathogen burden and high levels of systemic inflammation (IL-6) in the PROVIDE
cohort, EED is likely prevalent [13, 37]. As hypothesized by Lindenmayer et al (2014), in
this context, a vicious cycle of zinc deficiency and EED may contribute to increased
susceptibility to enterpathogen infection and risk of diarrhea [12]. Future research may
elucidate additional mechanisms linking zinc deficiency to viral diarrhea, including
immune-mediated and microbiome-related.

Limitations of the present analysis include the PROVIDE study sample size and single
measurements of serum zinc and breast milk. Our results require validation in larger
cohorts, ideally including serial zinc and breast milk measurements over the first year,
temporally related to diarrheal episodes. Collection of data on maternal zinc status would
also enhance our analysis. Interpretation of TAC data, particularly related to diarrhea
attribution, is a work-in-progress, and assay results near the limit of detection (Cq
30─35) may be less clinically meaningful [23].
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In summary, as oral rotavirus vaccines are adopted globally in national immunization
programs, complementary interventions to address the excess burden of rotavirus
diarrhea must be considered. The evidence provided here supports further assessment of
targeted zinc interventions for the prevention of not only rotavirus diarrhea, but all viral
diarrhea. Future directions should include targeted zinc supplementation trials designed
to test the public health value of zinc supplementation, in both infants and mothers, for
the prevention of viral diarrheas. Additionally, continued promotion of exclusive
breastfeeding through six months and improved sanitation will contribute to a
comprehensive approach to reducing diarrheal disease burden due to viruses. Finally,
further interrogation of the complex biologic mechanisms relating zinc deficiency to viral
diarrhea will contribute to enhanced interventions moving forward.
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